Submission of the manuscript is online via e-mail
ecgarticle@gmail.com or
cholerez@mail.ru

Tel: +7 903 250 5288

Editorial Correspondence e-mail
gastrossr@gmail.com


Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail
journal@cniig.ru

Tel: +7 917 561 9505

SCImago Journal & Country Rank

№ 12 (148) 2017

  • Уважаемые коллеги !
    Helicobacter pylori, открытый Робином Уорреном и описанный им совместно с Бэрри Маршаллом более тридцати лет назад, продолжает привлекать внимание исследователей различного профиля. Отражением заинтересованности профессионального сообщества проблемой H. pylori и ассоциированных с его присутствием заболеваний и состояний явилось посвящение ей тематического выпуска журнала «Экспериментальная и клиническая гастроэнтерология».
    Открывает выпуск проблемная статья Е. В. Рябиченко и соавторов (НИЦ эпидемиологии и микробиологии им Н. Ф. Гамалеи, г. Москва), посвящённая оценке роли кишечно-мозговой оси в патогенезе заболеваний, ассоциированных с присутствием H. pylori. Авторами проанализирован обширный массив специальной литературы, посвящённой способности этого микроорганизма оказывать не только локальные цитотоксические и провоспалительные эффекты, но и системное воздействие на организм хозяина посредством модуляции кишечно-мозговой оси через прямое нейротоксическое воздействие на рецепторный аппарат слизистой оболочки желудка и активацию воспалительных процессов в нервных окончаниях. В статье Н. В. Ширинской и соавторов (Омский государственный медицинский университет, г. Омск) проанализировано влияние фактора приёма нестероидных противовоспалительных препаратов на присутствие штаммов H. pylori определённого фенотипа. Авторы подчёркивают, что молекулярный механизм взаимодействия H. рylori и нестероидных противовоспалительных препаратов во многом остается неясным и требует дальнейшего изучения. Статья Э. М. Эседова, Д. С. Акбиевой, посвящённая влиянию эрадикационной противохеликобактерной терапии на уровень содержания провоспалительных цитокинов в желудочном соке, убедительно демонстрирует связь между неэффективной эрадикацией H. рylori и сохранением повышенного уровня провоспалительных цитокинов в желудочном соке.
    Н. В. Бакулиной и соавторами (Северо-Западный государственный медицинский университет им. И. И. Мечникова, г. Санкт-Петербург) представлены результаты первого в России описательного эпидемиологического исследования распространенности хеликобактерной инфекции среди врачей. Согласно полученным авторами данным, средний показатель инфицированности врачебного персонала лечебных учреждений составляет почти 60 %, причём возрастные группы врачей различаются по уровню инфицированности. Со вполне разделяемым редакционной коллегией журнала «Экспериментальная и клиническая гастроэнтерология» огорчением, авторы констатируют наличие низкого уровня информированности врачей о собственном хеликобактерном статусе и отсутствие у большинства респондентов убеждённости в целесообразности самодиагностики инфицирования H. pylori.
    В обзорной статье В. В. Цуканова и соавторов (НИИ медицинских проблем Севера, г. Красноярск), посвящённой оценке роли микробиоты в этиопатогенезе заболеваний желудка, подчёркнуто, что участие в их возникновении и развитии не исчерпывается H. pylori: согласно положениям Киотского (2015) и Европейского (2017) консенсусов, прочие бактерии, а также вирусы, грибы и паразиты способны играть здесь определённую роль.
    Участие Helicobacter pylori в патогенезе аллергических состояний проанализировано в статье Г. И. Дрынова и соавторов (Поликлиника № 1 УДП РФ, г. Москва). Опираясь на анализ данных доступной литературы и собственный клинический опыт, авторы заключают, что роль H. pylori при аллергической патологии изучена недостаточна и требует дальнейшего рассмотрения.
    Обзорная статья С. А. Алексеенко (Дальневосточный государственный медицинский университет, г. Хабаровск) посвящена экстрагастральным проявлениям хеликобактерной инфекции: идиопатической тромбоцитопенической пурпуре, железодефицитной и B 12-дефицитной анемии, атеросклерозу, ожирению, метаболическому синдрому, сахарному диабету, бронхиальной астме, болезням Альцгеймера и Паркинсона. Авторами подчёркнута необходимость дальнейшего изучения в соответствие с требованиями доказательной медицины потенциальной роли хеликобактерной инфекции в развитии экстрагастродуоденальных заболеваний.
    Вопросы выбора эрадикационной противохеликобактерной терапии с учётом растущего уровня приобретённой резистентности H. pylori к антибактериальным средствам освящены в обзорной статье Н. Н. Дехнич и соавторов (Смоленский государственный медицинский университет, г. Смоленск). Авторами предложены варианты эрадикационной терапии первой и второй линии для пациентов с непереносимостью различных антибактериальных препаратов, а также описаны варианты эмпирической терапии третьей линии при невозможности определения чувствительности Н. pylori к антимикробным препаратам после неэффективной терапии второй линии.
    Дисбиотические осложнения эрадикационной противохеликобактерной терапии рассмотрены в статье А. В. Волчецкого (Московский НИИ эпидемиологии и микробиологии им. Г. Н. Габричевского, г. Москва). Автором, проанализировавшим собственный клинический опыт, обосновывается необходимость предупреждения развития антибиотикассоциированных нарушений со стороны кишечной микрофлоры с помощью пробиотических и пребиотических препаратов. В статье М. Л. Колотиловой, Л. Н. Иванова (Первый Московский государственный медицинский университет им. И. М. Сеченова, г. Москва; Чувашский государственный университет имени И. Н. Ульянова, г. Чебоксары) представлена собственная «неврогенно-генетическая теория» этиопатогенеза язвенной болезни, опирающаяся на анализ данных литературы и собственный клинический опыт. По мнению авторов, включение в схемы эрадикационной противохеликобактерной терапии нейролептиков, анксиолитиков и препаратов общего седативного действия способно существенно повысить эффективность лечения язвенной болезни.
    Раздел «Дискуссия» представлен сообщениями И. А. Морозова и В. Ю. Голофеевского, каждое из которых содержит оригинальный авторский подход к различным аспектам проблемы участия H. pylori в этиопатогенезе заболеваний гастродуоденальной области. Так, В. Ю. Голофеевским (Военно-медицинская академия имени С. М. Кирова, г. Санкт-Петербург) обсуждаются логические противоречия сложившихся представлений о природе хронического гастрита, ошибки в его диагностике, а также предпринимается попытка критической оценки реальной роли H. pylori в возникновении и развитии этого заболевания. Автором предлагается новая (иерархическая, комбинационная) концепция формирования хронического гастрита, зачастую являющимся предраковым состоянием. В свою очередь, И. А. Морозовым (Институт полиомиелита и вирусных энцефалитов им. М. П. Чумакова, г. Москва) обсуждается проблема несостоятельности конвенциальных схем эрадикационной противохеликобактерной терапии и предлагается подход, базирующийся на отказе от применения таблетированных препаратов в пользу «жидкостной» технологии, позволяющей воздействовать непосредственно на популяцию H. pylori.
    По традиции в материал номера включена статья по истории медицины.
    Дорогие коллеги!
    Мы надеемся, что представленный в настоящем выпуске журнала «Экспериментальная и клиническая гастроэнтерология» материал окажется полезным как для научно-исследовательского поиска, так и для повседневной клинической практики.

    С пожеланием профессионального успеха,
    ответственный за выпуск,

      заведующий лабораторией индикации и ультраструктурного анализа микроорганизмов
    ФГБУ «НИЦЭМ им. Н. Ф. Гамалеи» МЗ РФ

    доктор медицинских наук, профессор
      Жуховицкий Владимир Григорьевич
       
    1. Federal research center of epidemiology and Microbiology them. N.F. Gamalei (Moscow, Russian Federation)
    2. Russian Medical Academy оf Continuing Professional Education (Moscow, Russian Federation)
    3. First MSMU n. a. I.M. Sechenov (Moscow, Russian Federation)

    Keywords: H.pylori , intestinal-brain axis, visceral sensitivity, cytokines

    Abstract: A complex combination of external factors (stress), host immune status and virulence factors determines the susceptibility and severity of the outcome of H. pneumonia infection and associated pathology. H.pylori and intestinal-brain axis relationships are bi-directional and affect the infection process and neuroendocrine immunological response of the host organism, including changes in secretory and motor functions of the digestive tract, modification of visceral sensitivity and cognitive functions. The effect of H.pylori on intestinal-brain axis is based on direct neurotoxic action, micronutrient deficiency, the activation of inflammatory processes in the epithelium, destruction of the barrier function, destabilization of the blood-brain barrier and the systemic action of pro-inflammatory cytokines.

      1. Bondarenko V.M., Ryabichenko E.V. Rol' nespetsificheskoi infektsii v razvitii ostroi i khronicheskoi vospalitel'noi patologii nervnoi sistemy. Epidemiologiya i infektsionnye bolezni. 2011;4:8–14.
      2. Bondarenko V.M., Ryabichenko E.V. Perspektivy patogeneticheskoi terapii pri patologii kishechno-mozgovoi osi. Verkhnevolzhskii meditsinskii zhurnal. 2016;15(1):17–23.
      3. Bercik P., Verdu E.F., Foster J.A., Lu J., Scharringa A., Kean I., Wang L., Blennerhassett P., Collins M.S. Role of gut-brain axis in persistent abnormal feeding behavior in mice following eradication of Helicobacter pylori infection. Am J Physiol Regul Integr Comp Physiol. 2009;296:R587–R594.
      4. Brzozowski T., Konturek S.J. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol. 2011;62:591–599.
      5. Budzyński J., Kłopocka M. Brain-gut axis in the pathogenesis of Helicobacter pylori infection. World J Gastroenterol. 2014;20(18):5212–5225.
      6. Burns M., Muthupalani S., Ge Z., Wang T.C., Bakthavatchalu V., Cunningham C., Ennis K., Georgieff M., Fox J.G. Helicobacter pylori Infection Induces Anemia, Depletes Serum Iron Storage, and Alters Local Iron-Related and Adult Brain Gene Expression in Male INS-GAS Mice. PLoS One. 2015;10(11);1371–1392.
      7. Carabotti M., Scirocco A., Maselli M.A., et al. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28(2):203–209.
      8. Chung-Che Tsai, Ting-Yu Kuo,† Zhi-Wei Hong,† Ying-Chieh Yeh. Helicobacter pylori neutrophil-activating protein induces release of histamine and interleukin-6 through G protein-mediated MAPKs and PI3K/Akt pathways in HMC-1 cells. Virulence. 2015;6(8):755–765.
      9. Ernst P.B., Gold B.D. The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu. Rev. Microbiol. 2000;54:615–640.
      10. Jones M.P. The role of psychosocial factors in peptic ulcer disease: beyond Helicobacter pylori and NSAIDs. J Psychosom Res. 2006;60:407–412.
      11. Katoh K., Nomura M., Nakaya Y., Iga A., Nada T., Hiasa A., Ochi Y., Kawaguchi R., Uemura N., Honda H., Shimizu I., Ito S. Autonomic nervous activity before and after eradication of Helicobacter pylori in patients with chronic duodenal ulcer. Aliment Pharmacol Ther. 2002;16(Suppl 2):180–186.
      12. Konturek P.C., Brzozowski T., Konturek S.J. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol. 2011;62:591–599.
      13. Kountouras J., Zavos C., Stergios A., Polyzos S.A. et al. The gut-brain axis: interactions between Helicobacter pylori and enteric and central nervous systems. Annals Gastroenterology. 2015;28:506–510.
      14. Masuda Y., Tanaka T., Inomata N. et al. Ghrelin stimulates gastric acid secretion and motility in rats. Biochem Biophys Res Commun. 2000;276:905–908.
      15. Meng W.P., Wang Z.Q., Deng J.Q., Liu Y., Deng M.M.,1 and Lü M.H. The Role of H. pylori CagA in Regulating Hormones of Functional Dyspepsia Patients. Gastroenterol Res Pract. 2016;2016:959–968.
      16. Sharkey K.A., Savidge T.C. Role of enteric neurotransmission in host defense and protection of the gastrointestinal tract. Auton Neurosci. 2014;181:94–106.
      17. Suzuki H., Matsuzaki J., Hibi T. Ghrelin and oxidative stress in gastrointestinal tract. J Clin Biochem Nutr. 2011;48:122–125.
      18. van Vliet A.H., Stoof J., Poppelaars S.W., et al. Differential Regulation of Amidase- and Formamidase-mediated Ammonia Production by the Helicobacter pylori Fur Repressor. J Biol Chem. 2003;278(11):9052–9057.
      19. Zhou H., Liang H., Li Z.F., Xiang H., Liu W., Li J.G. Vagus nerve stimulation attenuates intestinal epithelial tight junctions disruption in endotoxemic mice through alpha7 nicotinic acetylcholine receptors. Shock. 2013;40:144–151.


    Full text is published :
    Ryabichenko E.V., Burgasov O.A. , Zhukhovitskii V.G. THE ROLE OF INTESTINAL BRAIN AXIS IN THE PATHOGENESIS OF DISEASES ASSOCIATED WITH . Experimental and Clinical Gastroenterology Journal. 2017;148(12):4-8
    Read & Download full text

    1. Omsk State Medical Information-Analytical Centre (Omsk, Russian Federation)
    2. Omsk State Medical University (Omsk, Russian Federation)
    3. Omsk State Medical Diagnostic Center (Omsk, Russian Federation)

    Keywords: stomach, Helicobacter pylori, strains of non-steroidal anti-inflammatory drugs (NSAIDs)

    Abstract: The study included 34 patients (15 men and 19 women, average age 56,7±1,46). The test was divided into three groups, with the additional inclusion criterion of I and II groups was the use of a patient NSAIDs for at least 30 calendar days prior to the survey. A study of strains of Helicobacter pylori (HP) in gastric mucosa of adult patients receiving non-steroidal anti-inflamatory drugs (NSAIDs). HP genotyping was performed by PCR. In the General structure of the studied biopsy specimens was often identified genotype vac A s1/m1, cag A+; iceA1 (7 cases out of 34 (of 20.58 %), p<0.05). The distribution of genotypes in the clinical groups were quite heterogeneous, the Results of the conducted studies, despite some heterogeneity, indicate the presence of statistically significant differences depending on the presence of erosive-ulcerative changes and factors of NSAIDs.

      1. Telford J.L., Covacci A., Rappuoli R., Ghiara P. Immunobiology of Helicobacter pylori infection. Current Opinion Immunology. 1997;9(4):498-503.
      2. Walker M.M., Crabtree J.E. Helicobacter pylori infection and the pathogenesis of duodenal ulceration. Annals of the New York Academy Sciences. 1998;859:96-111.
      3. Ширинская Н.В., Ахмедов В.А. NPVP-gastropatiya i Helicobacter pylori: bol'she voprosov, chem otvetov. Eksperimental’naya i Klinicheskaya Gastroenterologiya – Experimental and Clinical Gastroenterology Journal. 2010;9:116-120.
      4. Huang J.Q., Sridhar S., Hunt R.H. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359:14-22.
      5. Hawkey C.J., Tulassay Z., Szczepanski L., et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet. 1998;352:1016-1021.
      6. Cover T.L., Blaser M.J. Purification and characterization of the vacuolating toxin from Helicobacter pylori. Journal of Biological Chemistry. 1992;267(15):10570-10575.
      7. Odenbreit S., Puls J., Sedlmaier B., Gerland E., Fischer W., Haas R. Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science. 2000;287(5457):1497-1500.
      8. Cover T.L. The vacuolating cytotoxin of Helicobacter pylori. Molecular Microbiology. 1996;20(2):241-246.
      9. Suzuki R., Shiota S., Yamaoka Y. Molecular epidemiology, population genetics, and pathogenic role of Helicobacter pylori. Infection Genetics and Evolution. 2012;12(2):203-213.
      10. Gu Q., Xia H.H., Wang W.H., Wang J.D., Wong W.M., Chan A. O. O., Yuen M. F., Lam S. K., Cheung H. K.-L., Liu X. G., Wong B. C.-Y. Effect of cyclo-oxygenase inhibitors on Helicobacter pylori susceptibility to metronidazole and clarithromycin. Alimentary Pharmacology and Therapeutics. 2004;20(6):675-681.
      11. Wang W.H., Wong W.M., Dailidiene D., Berg D.E., Gu Q., Lai K.C., Lam S.K., Wong B.C.Y. Aspirin inhibits the growth of Helicobacter pylori and enhances its susceptibility to antimicrobial agents. Gut. 2003;52(4):490-495.
      12. Wang W.H., Hu F.L., Wong B.C.Y, Lam S.K. Inhibitory effects of aspirin and indometacin on the growth of Helicobacter pylori in vitro. Chinese Journal of Digestive Diseases. 2002;3(4):172-177.
      13. Shirin H., Moss S.F., Kancherla S., Kancherla K., Holt P.R, Weinstein I.B. Sordillo E.M. Non-steroidal anti-inflammatory drugs have bacteriostatic and bactericidal activity against Helicobacter pylori. Journal of Gastroenterology and Hepatology. 2006;21(9):1388-1393.
      14. Ma H.X., Wang W.H., Hu F.L., et al. Effect of aspirin and celecoxib on Helicobacter pylori in vitro. Shijie Huaren Xiaohua Zazhi. 2006;14:2747-2752.
      15. Barkin J. The relation between Helicobacter pylori and nonsteroidal anti-inflammatory drugs. The American Journal of Medicine. 1998;105(5):22S-27S.
      16. Hudson N., Balsitis M., Filipowicz F., Hawkey C.J. Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut. 1993,34(6):748-751.
      17. Proença-Modena J.L., Acrani G.O., Brocchi M. Helicobacter pylori: phenotypes, genotypes and virulence genes. Future Microbiology. 2009;4(2):223-240.


    Full text is published :
    Shirinskaya N.V., Pomorgailo E.G., Akhmedov V.A., Vas'kina T.V., Kirichenko N.P. GENOTYPE HELICOBACTER PYLORI AT NSAIDS TAKING PATIENTS. Experimental and Clinical Gastroenterology Journal. 2017;148(12):9-13.
    Read & Download full text

    1. Federal State Budgetary and Educational Institution of Higher Education of the Russian Federation “Dagestan State Medical University” (Makhachkala, The Republic of Dagestan, Russian Federation)

    Keywords: chronic gastritis, peptic ulcer of duodenum, cytokines

    Abstract:: The aim of research was to evaluate the effectiveness of the effect of eradication therapy on the cytokine status of gastric juice in patients with chronic non-atrophic gastritis (HNG) and duodenal ulcer (duodenal ulcer) associated with Helicobacter pylori.
    Materials and methods. Clinical observations and laboratory-instrumental studies were performed in 95 patients aged 20 to 55 years with HNG and duodenal ulcer with determination of cytokine content of IL-1β, IL-6 and TNF-α in the fasting portion of gastric juice.
    Results. The most pronounced decrease in the content of proinflammatory cytokines in gastric juice on the background of treatment was found in patients of the 1st group who received combined therapy according to the scheme omeprazole ++ clarithromycin + amoxicillin. Analysis of the content of proinflammatory cytokines (IL-1β, IL-6 and TNF-α) in gastric juice in patients with acute exacerbation showed that their concentration in all 8 patients after the course of therapy exceeded the norm (P <0.05) and was IL–1β — 30,30 + 1,15 pg / l, IL-6–10,4 + 0,83 pg / l and TNF-α — 32,5 + 1,13 pg / l. At the same time, the level of proinflammatory cytokines in gastric juice correlated with the degree of dissemination of H. pylori in the mucosa of the gastroduodenal zone.
    Сonclusion. Helicobacter pylori infection in inflammation and ulceration in the mucous membrane of the stomach and duodenum, possibly in addition to other mechanisms, affects the activation of proinflammatory cytokines (IL-1beta, IL-6, TNF-alpha) in gastric juice. Incomplete eradication of H. рylori after treatment during clinical endoscopic remission in patients with duodenal ulcer in the vast majority of cases is accompanied by the preservation of an increased level of pro-inflammatory cytokines in gastric juice, which may be one of the reasons for the relapse of the disease.

      1. Ageeva E.S. Assotsiatsiya polimorfizmov genov G-174 CIL6 i T-251A IL8 s yazvennoi bolezn'yu u Khakasov. Immunologija. 2010;31(3):131-133.< /li>
      2. Maev I.V. Sovremennye standarty lechenija kislotozavisimyh zabolevanij, associirovannyh s Helicobacter pylori. Materialy konsensusa «Maastriht-3». Consilium Medicum. Pril.: Gastroenterologiya. 2006;1 pp. 3–8.
      3. Maev I.V. Vazhnye prakticheskie rezul'taty i sovremennye tendentsii v izuchenii zabolevanii zheludka i dvenadtsatiperstnoi kishki. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology 2012;4:17-26.
      4. Oradova A.Sh., Ustenova G.O., Stabaeva G.S. Metody issledovaniya tsitokinov [Methods of cytokine research]. Medicine. 2014;10:84-87
      5. Osadchuk M.M. Khelikobakterioz. Aktual'nye i nereshennye problemy patogeneza i lecheniya. Prakticheskaya meditsina. 2012;56(1):16-21.
      6. Stepchenko A.A. Uroven' pro- i protivovospalitel'nykh tsitokinov, fenotip okislitel'nogo metabolizma u bol'nykh yazvennoi bolezn'yu, assotsiirovannoi s razlichnymi shtammami Helicobacter pylori. Kurskii nauchno-prakticheskii vestnik «Chelovek i ego zdorov'e». 2010;3:134-139.
      7. Bayraktaroglu T. Serum levels of tumor necrosis factor-a, interleukin-6 and interleukin-8 are not increased in dyspeptic patients with Helicobacter pylori – associated gastritis. Mediators of inflammation. 2004;13(1):25-28.
      8. Kasifoglu N. IL8 serum levels in patients with Helicobacter pylori infection and relation between serological marcers. African journal of microbiology research. 2009;3(11):822-825.


    Full text is published : Esedov E.M., Akbieva D.S. EFFECTIVENESS OF THE EFFECTS OF ERADICATION THERAPY ON THE CONTENT OF PROINFLAMMATORY CYTOKINES IN GASTRIC JUICE IN PATIENTS WITH CHRONIC GASTRODUODENAL DISEASES ASSOCIATED WITH. Experimental and Clinical Gastroenterology Journal. 2017;148(12):14-19
    Read & Download full text

    1. North-Western State Medical University n. a. I.I. Mechnikov (Saint Petersburg, Russian Federation)
    2. SM–clinic (Saint Petersburg, Russian Federation)

    Keywords: Helicobacter pylori, epidemiology of H. pylori, H. pylori and physicians, 13С-urea breath test, anti-helicobacter therapy, eradication

    Abstract: The article presents the results of the first observation epidemiological study on H. pylori infection among physicians (therapists). 1154 doctors from 14 different regions of Russian Federation were examined by using 13С-urea breath test. High prevalence of H. pylori (59 %) among doctors was found. The prevalence of H. pylori among doctors according to the different regions and age groups of doctors was estimated. The prevalence of H. pylori in the group of doctors under the age of 30 y. o. was 45,2 %, in the group of 51–60 y. o. — 65,2 %, respectively. Treatment for eradication H. pylori among 619 of H. pylori-positive doctors was received only 114 (18.9 %) doctors and therapy achieved elimination of the infection in 69.2 % cases.

      1. Malfertheiner P., Megraud F., O’Morain C.A. et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30.
      2. IARC Helicobacter pylori Working Group. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. Lyon, France: International Agency for Research on Cancer (IARC Working Group Reports, No. 8); pp. 174–180.
      3. Hooi J.K., Lai W.Y., Ng W.K., Suen M.M.Y., Underwood F.E., Tanyingoh D., Malfertheiner P., Graham D.Y., Wong V.W.S., Wu J.C.Y., Chan F.K.L., Sung J.J.Y., Kaplan G.G., Ng S.C. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153(2):420–429.
      4. Abdulkhakov R.A., Abdulkhakov S.R. Epidemiologiya Helicobacter pylori. Prakticheskaya meditsina. 2006;18(4):2–3.
      5. Roman L., Lukyanchuk R., Sablin O. Prevalence of H. pylori Infection and Atrophic Gastritis in a Population-based Screening with Serum Biomarker Panel (GastroPanel®) in St. Petersburg. Anticancer Res. 2016;36(8):4129–4138.
      6. Rakhmanin Yu.A., Zykova I. E., Fedichkina T. P. i dr. Izuchenie territorial'nogo raspredeleniya infitsirovannosti Helicobacter pylori trudosposobnogo naseleniya g. Moskvy v khode dispanserizatsii proizvodstvennykh kontingentov. Gigiena i sanitariya. 2013;92(5):79–82.
      7. Kurilovich S.A., Reshetnikov O.V. Epidemiologicheskie issledovaniya v gastroenterologii: mnogoletnii sibirskii opyt izucheniya Helicobacter pylorii assotsiirovannykh zabolevanii. Eksperimental'naya i klinicheskaya gastroenterologiya – Experimental and Clinical Gastroenterology Journal. 2015;3:4–10.
      8. Tsukanov V.V., Amel'chugova O.S., Butorin N.N. et al. Sovremennye aspekty eradikatsii Helicobacter pylori. Ter. arkhiv. 2013;2:73–5.
      9. Zakharova N.V., Simanenkov V. I., Bakulin I.G., Sablin O.A., Il'chishina T.A., Zakharov D.V. Rasprostranennost' khelikobakternoi infektsii u patsientov gastroenterologicheskogo profilya v Sankt-Peterburge. Farmateka. 2016;5(16):33–39.
      10. Brown L.M. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol. Rev. 2000;22:2:283–97.
      11. Mastromarino P., Conti C., Donato K., Strappini P.M., Cattaruzza M.S., Orsi G.B. Does hospital work constitute a risk factor for Helicobacter pylori infection? The Journal Hospital Infecion. 2005;60(3):261–268.
      12. Peters C., Schablon A.,1 Harling M.,1 Claudia Wohlert C., J.T., Nienhaus A. The occupational risk of Helicobacter pylori infection among gastroenterologists and their assistants. BMC Infect Dis. 2011;31(11):154.
      13. Mastromarino P. et al. Helicobacter pylori infection among healthcare workers: further investigation is needed. J Hosp Infect. 2007;66(3):297–298.
      14. Kim H.Y., Kim N., Kim S. M. et al. Seroprevalence of Helicobacter pylori infection in Korean Health Personnel. Gut Liver. 2013;7(6):648–654.
      15. Zakharova, N.V., Simanenkov V. I., Savilova I. V., Svarval' A. V. Helicobacter pylori – izotopnaya diagnostiki infektsii i testirovanie rezistentnostiyu. Farmateka. 2016;2:24–27.
      16. Matysiak-Budnik T., Mégraud F. J. Epidemiology of Helicobacter pylori infection with special reference to professional risk. Physiol Pharmacol. 1997;48(Suppl 4):3–17.
      17. Hildebrand P., Meyer-Wyss B.M., Mossi S., Beglinger C. Risk among gastroenterologists of acquiring Helicobacter pylori infection: casecontrol study. BMJ. 2000;15:321–349.
      18. Birkenfeld S., Keter D., Dikman R. et al. Predominio de la infección de los píloros de Helicobacter en el personal del Salud-Cuidado de las clínicas primarias del cuidado y de la gastroenterología. Diario de la Gastroenterología Clínica. 2004;38:19–23.
      19. Nagy P., Johansson S., Molloy-Bland M. Systematic review of time trends in the prevalence of Helicobacter pyloriinfection in China and the USA. Gut Pathog. 2016;8:8. doi:10.1186/s13099-016-0091-7
      20. Xia P., Ma M. F., Wang W. Status of Helicobacter pylori infection among migrant workers in Shijiazhuang, China. Asian Pac J Cancer Prev. 2012;13(4):1167–1170.
      21. Shtygasheva O. V. Rasprostranennost' infektsii Helicobacter pylori i chastota dispepsicheskikh zhalob u naseleniya. Rossiiskii zhurnal gastroenterologiii, gepatologii, koloproktologii. 2004;1:33–36.
      22. Svarval' A.V., Ferman R. S., Zhebrun A. B. Izuchenie dinamiki prevalentnosti infektsii, obuslovlennoi Helicobacter pylori, sredi razlichnykh vozrastnykh grupp naseleniya Sankt-Peterburga v 2007–2011 godakh. Infektsiya i immunitet. 2012;2(4):741–746.
      23. Goto T., Haruma K., Kamata T. et al. Marked decrease of Helicobacter pylori infection in asymptomatic children in Japan. Gut. 1996;39(Suppl. 2):481.


    Full text is published :
    Bakulina N.V., Simanenkov V.I., Bakulin I.G., Ilchishina T.A. PREVALENCE OF HELICOBACTER PYLORI INFECTION AMONG PHYSICIANS . Experimental and Clinical Gastroenterology Journal.2017;148(12):20-24.
    Read & Download full text

    1. Moscow Scientific-Research Institute of epidemiology and microbiology (Moscow, Russian Federation)

    Keywords: probiotic and prebiotic products, prevention of dysbiosis, eradication therapy

    Abstract: The article shows the causal factors in the development of gastric ulcer, current approaches to the treatment and eradication treatment. The aim of the research was to study the clinical efficacy and tolerability of synbiotic «Normospectrum» in complex therapy of diseases of the stomach and duodenum. 44 people aged 17 to 53 years (the major group) received «Normospectrum». The control group consisted of 47 people of similar age who did not receive the drug. Analysis of clinical characteristics showed that patients receiving «Normospectrum», the improvement of health and the relief of symptoms of disorders of the gastrointestinal tract in the main group was 2–5 days earlier than patients in the control group, 65 % of patients. Positive clinical dynamics was confirmed in conducting a urease breath test. The test was performed at admission of patients and after the eradication therapy. Patients of the main group the positive effects of the ongoing eradication therapy on the background of the «Normospectrum» according to the urease breath test was 89 %, while patients in the control group to 71 %.

      1. Vasilenko V.Kh. Chego my ne znaem o yazvennoi bolezni (puti izucheniya problemy). Aktual'nye voprosy gastroenterologii. Moscow, 1970; vol. 1, pp.3-17.
      2. Warren J.R., Marshall B.J. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet, 1983;1:1311-1315.li>
      3. Isakov V.A., Domaradskii I.V. Khelikobakterioz. Moscow, 2003. 412 p.
      4. Baranskaya E.K. Yazvennaya bolezn' i infektsiya Helicobacter pylori. Russkii Meditsinskii Zhurnal. 2000; 1:8-14.
      5. Minushkin O.N., Aronova O.V. Sovremennyi vzglyad na problemu eradikatsii Helicobacter pylori. Praktikuyushchii vrach. 2002;1:52-54.
      6. Tsimmerman Ya.S., Vedernikov V.E., Novikov V.N., Kas'yanova N.L. Mikroflora slizistoi obolochki lukovitsy dvenadtsatiperstnoi kishki i ee rol' v patogeneze retsidiva yazvennoi bolezni. Sib. zhurn. gastroenterol., gepatol. 2001;12-13: 61-63.
      7. Ardatskaya M.D., Minushkin O.N., Ikonnikov N.S. Disbakterioz kishechnika: ponyatie, diagnosticheskie podkhody i puti korrektsii. Vozmozhnosti i preimushchestva biokhimicheskogo issledovaniya kala. Posobie dlya vrachei. Moscow, 2004.
      8. Bondarenko V.M., Gracheva N.M., Matsulevich T.V. Disbakteriozy kishechnika u vzroslykh. Moscow, 2003. 224 p./li>
      9. Korshunov V.M., Efimov B.A., Pikina A.P. Kharakteristika biologicheskikh preparatov i pishchevykh dobavok dlya funktsional'nogo pitaniya i korrektsii mikroflory kishechnika. Zhurn. mikrobiol. 2000; 3:86-91.
      10. Maev I.V., Samsonov A.A., Golubev N.N. Antibiotikoassotsiirovannaya diareya. Gastroenterologiya. 2007;1:45-49.
      11. Osipov G.A., Parfenov A.I., Verkhovtseva N.V., Ruchkina I.N., Kurchavovo V.A., Boiko N.B., Rogatina E.L. Klinicheskoe znachenie issledovaniya mikroorgani и zmov slizistoi obolochki kishechnika kul'tural'no–biokhimicheskim i khromato–mass–spektrometricheskim metodami. Eksperimental'naya i klinicheskaya gastroenterologiya – Experimental and Clinical Gastroenterology Journal. 2003; 4:59-67.
      12. Aleshkin A.V., Isaev R.R., Rubal'skii O.V., Amerkhanova A.M., Panov A.A. Sinbiotik Normospektrum v lechenii zabolevanii zheludka i dvenadtsatitiperstnoi kishki. Vestnik Rossiiskogo gosudarstvennogo meditsinskogo universiteta. 2009;2:19-22


    Full text is published :
    Volchetski A.L. INTESTINAL DYSBIOSIS AS A CONSEQUENCE OF ERADICATION THERAPY H. PYLORI AND A NEW APPROACH TO ITS CORRECTION.Experimental and Clinical Gastroenterology Journal . 2017;148(12):25-29
    Read & Download full text

    1. Kirov state medical university under the Ministry of Health of the Russian Federation (Kirov, Russian Federation)

    Keywords: coronary heart disease, gastroduodenal pathology, Нelicobacter pylori, morphological status, kristalloskopiya of saliva

    Abstract:Aim. The comparative analysis of the functional and morphological status of patients with coronary heart disease (CHD) with a combination of gastroduodenal pathology against the background of different options of treatment of gastroduodenal pathology (GDP). Subjiects and methods. In the course of the open prospective research features of a current of CHD in case of a combination to the GDP associated with Helicobacter pylori(n=147) in comparison with the patients of CHD who don’t have the GDP (n=147) were studied. For the purpose of studying of influence of different options of treatment of the GDP оn efficiency of treatment of sick CHD patients were divided into three groups. Patients of the I group received eradikatsionny + basic therapy, patients of the II group received antisekretorny + basic therapy. The III group was constituted by patients with the isolated CHD, receiving only therapy. Estimated dynamics of the morphological status and kristallogenny activity of saliva. Results. At sick CHD in case of a combination to the GDP the morphological pattern of the expressed inflammatory process, significant lowering of kristallogenny activity and violation of dehydrational structurization of saliva is revealed. After treatment (eradikatsionny + basis therapy) at 94,6 % of patients of the I group permanent endoscopic remission of a gastroduodenal zone, normalization of kristallogenny activity of the facies of saliva was marked. Conclusion. Inclusion of eradikatsionny therapy in an algorithm of treatment of sick CHD from the GDP associated with Helicobacter pylori along with achievement of kliniko-morphological remission of a gastroduodenal zone promotes increase in extent of restoration of dehydrational structurization of saliva in comparison with antisekretorny therapy.

      1. Alekseeva O.P., Pikulev D.V., Dolbin I.V. Ishemicheskaya bolezn' serdtsa i gastroezofageal'naya reflyuksnaya bolezn': sindrom vzaimnogo otyagoshcheniya (Klinicheskaya illyustratsiya). Klinicheskie perspektivy v gastroenterologii, gepatologii. 2012;3:31-34.
      2. Zvenigorodskaya L.A., Bondarenko E.Yu., Morozov I.A., Chikunova B.Z. Yazvennaya bolezn' u pozhilykh: klinicheskie osobennosti i znachenie H.pylori. Klinicheskaya gerontologiya. 2007;13(1):9-14.
      3. Pavlov O.N. Nositel'stvo Helicobacter pylori kak skrytyi sistemnyi faktor riska. Meditsinskii al'manakh. 2011;13(4):125-130.
      4. Kratnov A.E., Pavlov O.N. Infektsiya Helicobacter pylori i sostoyanie antioksidantnoi zashchity u patsientov s nestabil'nym techeniem ishemicheskoi bolezni serdtsa. Eksperimental'naya i klinicheskaya gastroenterologiya – Experimental and Clinical Gastroenterology Journal. 2004;5:4-9.
      5. Simonova Zh.G., Martusevich A.K. Otsenka effektivnosti eradikatsionnoi terapii u patsientov s sochetaniem yazvennoi bolezni zheludka i ishemicheskoi bolezni serdtsa. Vrach-aspirant. 2012;55(6):28-33.
      6. Martusevich A.K., Kolevatykh E.P. Kristalloskopicheskaya kartina biozhidkostei pri yazvennoi bolezni. Eksperimental'naya i klinicheskaya gastroenterologiya – 2006;6:35-40
      7. Martusevich A.K., Kamakin N.F., Simonova Zh.G. Molekulyarnye mekhanizmy strukturoobrazovaniya v vysykhayushchikh kaplyakh biologicheskikh substratov. Vyatskii meditsinskii vestnik. 2011;2:32-38.
      8. Maev I.V., Samsonov A.A., Golubev N.N., Kucheryavyi Yu.A., Belyavtseva E.V., Korovina T.I., Barkalova E.V. Khelikobakter-assotsiirovannaya forma yazvennoi bolezni zheludka i dvenadtsatiperstnoi kishki: problemy terapii. Farmateka – Pharmateca. 2011;215(2):10-17.
      9. Bakuev M.M., Saidov M.Z., Butakov A.A. Osobennosti sekretsii mieloperoksidazy i khemilyuminestsentnogo otveta neitrofilov cheloveka pri kontakte so stimulyatorami razlichnoi prirody. Immunologiya. 1991;1:15-17.
      10. Franceschi F., Niccoli G., Ferrante G., Gasbarrini A., Baldi A., Candelli M., Feroce F., Saulnier N., Conte M., Roccarina D., Lanza G.A., Gasbarrini G., Gentiloni S.N., Crea F. CagA antigen of Helicobacter pylori and coronary instability: insight from a clinico-pathological study and a meta-analysis of 4241 cases. Atherosclerosis. 2009;202(2):535-542.
      11. Stone A.F., Mendall M.A., Kaski J.C., Edger T.M., Risley P., Poloniecki J., Camm A.J., Northfield T.C. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA): STAMINA. Circulation. 2002;106(10):1219-1223.
      12. Pellicano R., Fagoonee S., Rizzetto M., Ponzetto A. Helicobacter pylori and coronary heart disease: which directions for future studies? Critical Reviews in Microbiology. 2003;29(4):351-359.
      13. Zhang S.et al. Cytotoxin-associated gene-A-seropositive virulent strains of Helicobacter pylori and atherosclerotic diseases: a systematic review. Chinese Medical Journal. 2008;121(10):946-951.


    Full text is published :
    Simonova Zh.G., Martusevich A.K. FEATURES OF THE FUNCTIONAL AND MORPHOLOGICAL STATUS OF PATIENTS WITH CORONARY HEART DISEASE AT A COMBINATION TO GASTRODUODENAL PATHOLOGY. Experimental and Clinical Gastroenterology Journal. 2017;148(12):30-36
    Read & Download full text

    1. FSEBI of HE «The Ulianov Chuvash State University» (Cheboksary, Russian Federation)
    2. SAI APE «Postgraduaute Medical Institute» of the Ministry of Health of the Chuvash Republic» (Cheboksary, Russian Federation)
    3. AI «Republican Clinical Oncology Centre» of the Ministry of Health of the Chuvash Republic (Cheboksary, Russian Federation)

    Keywords: irritable bowel syndrome, diagnostic criteria, extent of examinations, diff erential diagnostics

    Abstract: Introduction. Clinical signs of the irritable bowel syndrome (IBS) are not specific and can accompany other organic diseases. Following only the Rome criteria eligibility and the anxiety syndrome occurrence may result in diagnostic pitfalls and delayed diagnosis of grave diseases. In Russian gastroenterology IBS has always been and is still considered a diagnosis by exclusion. That is why IBS cannot by called a diagnosis found during the first visit to a physician. IBS is a diagnosis by exclusion that can be made only a patient’s systematic evaluation. Materials and methods. The article represents three clinical observations of patients with IBS. Diagnoses were made in full concordance with the Rome criteria. Nevertheless systematic evaluation according to the Clinical recommendations of the Russian Gastroenterological Association (RGA) revealed other diseases. Conclusions. Verification of the IBS diagnosis demands great responsibility on the side of a physician. To avoid diagnostic mistakes it is necessary to use all the examination procedures regulated in the Russian clinical recommendations.

      1. Ivashkin V.T., Shelygin Yu.A., Baranskaya E.K., Belousova E.A., Vasil'ev S.V., Golovenko O.V., Golovenko A.O., Grigor'ev E.G., Kostenko N.V., Kashnikov V.N., Kulikovskii V.F., Lapina T.L., Maev I.V., Poluektova E.A., Rumyantsev V.G., Timerbulatov V.M., Tikhonov A.A., Trukhmanov A.S., Fomenko O.Yu., Khalif I.L., Khubezov D.A., Chashkova E.Yu., Chibisov G.I., Sheptulin A.A., Shifrin O.S., Yanovoi V.V.Klinicheskie rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii i Assotsiatsii koloproktologov Rossii po diagnostike i lecheniyu bol'nykh s sindromom razdrazhennogo kishechnika. Rossiiskii zhurnal gastroenterologii, gepatologii, kolonoproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;2:43-49.
      2. Ivashkin V.T., Shelygin Yu.A., Baranskaya E.K., Belousova E.A., Beniashvili A.G., Vasil'ev S.V., Golovenko A.O., Golovenko O.V., Grigor'ev E.G., Kostenko N.V., Lapina T.L., Loranskaya I.D., Lyashenko O.S., Maev I.V., Poluektova E.A., Rumyantsev V.G., Timerbulatov V.M., A.S. Trukhmanov A.S., Fomenko O.Yu., Khalif I.L., Chashkova E.Yu., Sheptulin A.A., Shifrin O.S., Yanovoi V.V.Klinicheskie rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii i Assotsiatsii koloproktologov Rossii po diagnostikei lecheniyu sindroma razdrazhennogo kishechnika. Rossiiskii zhurnal gastroenterologii, gepatologii, kolonoproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017; 27(5):76-93.
      3. Andreev D.N., Zaborovskii A.V., Trukhmanov A.S., Maev I.A., Ivashkin V.T. Evolyutsiya predstavlenii o funktsional'nykh zabolevaniyakh zheludochno-kishechnogo trakta v svete Rimskikh kriteriev IV peresmotra (2016 g.). Rossiiskii zhurnal gastroenterologii, gepatologii, kolonoproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(1):4-11.
      4. Pimanov S.I. Silivonchik N.N. Rimskie IV rekomendatsii po diagnostike i lecheniyu funktsional'nykh gastroenterologicheskikh rasstroistv. Moscow, 2016. 160 p.
      5. Sheptulin A.A., Vize-Khripunova M.A. Sravnitel'naya otsenka amerikanskikh, nemetskikh, frantsuzskikh i rossiiskikh rekomendatsii povedeniyu bol'nykh s sindromom razdrazhennogo kishechnika. Rossiiskii zhurnal gastroenterologii, gepatologii, kolonoproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;2:92-101.
      6. Sheptulin A.A. Sindrom razdrazhennogo kishechnika: chto my vidim «vnutri khrustal'nogo shara»? Russkii meditsinskii zhurnal. Gastroenterologiya. – 2014;20:1437-1441.
      7. Butorova L.I., Tokmulina G.M. Sindrom razdrazhennogo kishechnika: osnovnye printsipy diagnostiki i lecheniya v poliklinicheskoi praktike. Moscow, Prima Print, 2014. 96 p.
      8. Tarasova L.V., Trukhan D.I. Bolezni kishechnika. Klinika, diagnostika i lechenie. Saint Petersburg, SpetsLit, 2013. 144 p.
      9. Loranskaya I.D., Lavrent'eva O.A. Sistemnyi podkhod k lecheniyu sindroma razdrazhennogo kishechnika. Russkii meditsinskii zhurnal. 2012;15:758-761.


    Full text is published :
    Tarasova L.V., Busalayeva E.I., Zhuchkova S.М. IS IT SO EASY TO DIAGNOSE IRRITABLE BOWEL SYNDROME? Experimental and Clinical Gastroenterology Journal. 2017;148(12):37–40
    Read & Download full text

    1. Voronezh State Medical University named after N. N. Burdenko (Voronezh, Russian Federation)

    Abstract: The purpose of this research was to study efficiency of Remaxol inclusion in complex therapy scheme for patients with chronic viral hepatitis C, genotype 3a. The analysis of treatment of 93 patients (43 men and 50 women) with verified diagnosis: medium-heavy form of chronic HCV, 3a genotype during replication phase (RNA HCV +) was performed. Patients’ average age was 42.8 ± 13.4 years, the duration of the disease was up to 5 years. Depending on the regimen of therapy patients were divided into two groups. 46 patients were included in main group. In addition to combined antiviral therapy (Pegintron and Ribavirin 24-week course) they received intravenously drip of Remaxol (400 ml 1 once a day during 12 days). Patients of the control group (n = 47) received only antiviral therapy. Clinical indicators dynamics were assessed (asthenic vegetative syndrome, hepatosplenomegaly, etc.) and, additionally, complexed laboratory studies were conducted: viral RNA detection with determination of the genotype, examination of antibody response levels, biochemical indicators (ALAT, AST, alkaline phosphatase, γ-glutamyl transpeptidase, total bilirubin) and cytokine profile (level of TNF-α, interleukins 2, 4 and 10). Medical test (liver biopsy by Mengini) was performed on 22 patients twice: not earlier than 6 months before the beginning of therapy and after the end of treatment. Our study revealed that remaxol therapy has a positive effect on clinical course of HCV serotype 3a by reducing severity of major clinical syndromes (asthenic vegetative syndrome and cholestatic syndrome). Twelve-day course of Remaxol helps to improve functional state of liver, improves membrane stabilizing and anti-cholestatic effects, which is confirmed by decrease in main biochemical indicators of hepatocellular damage — cytolysis and cholestasis. Inclusion of the drug in therapy in patients with chronical HCV, serotype 3a, increases cytoprotection and immunocorrection and, all in all, effectiveness of treatment.

      1. O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiiskoi Federatsii v 2015 godu: Gosudarstvennyi doklad [On the state of sanitary and epidemiological welfare of the population in the Russian Federation in 2015: State report]. Moscow, Federal'naya sluzhba po nadzoru v sfere zashchity prav potrebitelei i blagopoluchiya cheloveka. 2015. 115 p.
      2. Tselikovskii A.V., Pritulina Yu. G., Astapchenko D. S., Shentsova V. V., Krivoruchko I. V. Vliyanie steatoza pecheni na effektivnost' kombinirovannoi protivovirusnoi terapii khronicheskogo gepatita C [Influence of steatosis of the liver on the effectiveness of combined antiviral therapy of chronic hepatitis C.]. Sovremennye problemy nauki i obrazovaniya – Modern problems of science and education. 2012; 6: 186.
      3. Yan Z, Wang Y, Viral and host factors associated with outcomes of hepatitis C virus infection (Review). Molecular Medicine Reports. 2017; 15(5):2909–2924. doi: 10.3892/mmr.2017.6351.
      4. Gheonea D.I., Drocaş A.I., Mitroi G., Dobriţoiu M., Comănescu M.V., Stănculescu A.D., Cioboată R., Jieanu C.F., Tomescu P.I. The impact of liver steatosis on early and sustained treatment response in chronic hepatitis C patients. Romanian Journal Morphology and Embryology. 2017;58(1):107-113.
      5. Ivashkin V.T., Maevskaya M.V. Klinicheskie rekomendatsii po diagnostike i lecheniyu nealkogol'noi zhirovoi bolezni pecheni Rossiiskogo obshchestva po izucheniyu pecheni i Rossiiskoi gastroenterologicheskoi assotsiatsii [Clinical recommendations for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for the Study of the Liver and the Russian Gastroenterological Association]. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2016,2:24–42.
      6. Rekomendatsii po diagnostike i lecheniyu vzroslykh bol'nykh s gepatitom C [Recommendations for the diagnosis and treatment of adult patients with hepatitis C.] M., 2017, 69 p.
      7. Mato J. M., Martnez-Chantar M. L., Lu S. C. Methionine metabolism and liver disease. Annual Review of Nutrishion. 2008; 28: 273–93. doi: 10.1146/annurev.nutr.28.061807.155438
      8. Vlasov A.P., Bunyatyan N. D., Baranova O. N., Shibitov V. A., Vlasov P. A., Anaskin S. G. Patogeneticheskii podkhod k korrektsii enteral'noi nedostatochnosti [Pathogenetic approach to correction enteral insufficiency]. Klinicheskaya farmakologiya i terapiya. 2012;21(2):79–82.
      9. Mitsura V.M., Zhavoronok S. V., Krasavtsev E. L., Pav-lovich I. L., Suetnov O. N., Grushko T. P. Soderzhanie tsitokinov v syvorotke krovi bol'nykh khronicheskim gepatitom S pri interferonoterapii i kombinirovannoi terapii al'fa-interferonom i Ronkoleikinom Immunologiya, allergologiya, infektologiya. [The content of cytokines in the blood serum of patients with chronic hepatitis C with interferon therapy and combined therapy with alpha interferon and Roncoleukin]. Immunologiya, allergologiya, infektologiya. 2003;2:98–101.


    Full text is published :
    Pritulina Yu.G., Salomakhin G.G., Fil G.V. EFFECTIVENESS OF USE OF REMAXOL HEMATOPHYLENE PROTECTOR IN COMPLEX THERAPY OF CHRONIC HEPATITIS C.Experimental and Clinical Gastroenterology Journal. 2017;148(12):41-46
    Read & Download full text

    1. Federal state budget scientific institution «Federal research centre “of the Krasnoyarsk scientific center of the Siberian branch of the Russian Academy of Sciences”» (Krasnoyarsk, Russian Federation)

    Keywords: microbiome, microflora, stomach, H. pylori, pathology

    Abstract: The publication in 1984 in the Lancet of Australian authors R. Warren and B. Marshall about the discovery Helicobacter pylori was the first stage of revolutionary changes of views on the development of gastric pathology. Beginning the 21st century was marked by the proof of the existence in the stomach of a large number of other microorganisms. The second stage of the revolution was verified by the Kyoto consensus about gastritis and European Maastricht 5 consensus, confirmed the possibility of vital activity and association with gastric pathology of various bacteria, viruses and fungi.

      1. Marshall B.J., Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1(8390):1311–1315.
      2. Kazor C.E., Mitchell P.M., Lee A.M., Stokes L.N., Dewhirst F.E., Paster B.J. Diversity of bacterial populations on the tongue dorsa of patients with halitosis and healthy patients. Journal of Clinical Microbiology. 2003;41(2):558–563.
      3. Fraher M.H., O’Toole P.W., Quigley E.M. Techniques used to characterize the gut microbiota: a guide for the clinician. Nature Reviews Gastroenterology & Hepatology. 2012;9(6):312–322.
      4. Bik E.M., Eckburg P.B., Gill S.R., Nelson K.E., Purdom E.A., Francois F., Perez-Perez G., Blaser M.J., Relman D.A. Molecular analysis of the bacterial microbiota in the human stomach. Proc. Natl. Acad. Sci. USA. 2006;103(3):732–737.
      5. . Li X.X., Wong G.L., To K.F, Wong V.W.-S., Lai L.H., Chow D.K.L., Lau J.Y.-W., Sung J.-Y., Ding C. Bacterial microbiota profiling in gastritis without Helicobacter pylori infection or non-steroidal anti-inflammatory drug use. PLoS One. 2009;4(11):e7985.
      6. Engstrand L., Lindberg M. Helicobacter pylori and the gastric microbiota. Best Practice & Research Clinical Gastroenterology. 2013;27(1):39-45.
      7. Delgado S., Cabrera-Rubio R., Mira A., Suárez A., Mayo B. Microbiological survey of the human gastric ecosystem using culturing and pyrosequencing methods. Microbial Ecology. 2013;65(3):763–772.
      8. Cao L., Yu J. Effect of Helicobacter pylori Infection on the Composition of Gastric Microbiota in the Development of Gastric Cancer. Gastrointestinal Tumors. 2015;2(1):14–25.
      9. Tan M.P., Kaparakis M., Galic M., Pedersen J., Pearse M., Wijburg O.L.C., Janssen P.H., Strugnell R.A. Chronic Helicobacter pylori infection does not significantly alter the microbiota of the murine stomach. Appl. Environ. Microbiol. 2007;73(3):1010–1013.
      10. Khosravi Y., Dieye Y., Poh B.H., Ng C.G.,Loke M.F., Goh K.L.,Vadivelu J. Culturable bacterial microbiota of the stomach of Helicobacter pylori positive and negative gastric disease patients. Scientific World Journal. 2014;2014:610421.
      11. Sheh A., Fox J.G. The role of the gastrointestinal microbiome in Helicobacter pylori pathogenesis. Gut Microbes. 2013;4(6):505–531.
      12. Iizasa H., Ishihara S., Richardo T., Timmy Richardo T., Kanehiro Y., Yoshiyama H. Dysbiotic infection in the stomach. World Journal of Gastroenterology. 2015;21(40):11450–11457.
      13. Butorin N.N., Bichurina T.B., Tsukanov V.V., Kasparov E.V., Kuklin D.V., Timoshenko V.O., Shtygasheva O.V., Maady A.S., Vasyutin A.V. Rasprostranennost' i klinicheskie aspekty pishchevoda Barretta u naseleniya Vostochnoi Sibiri. Terapevticheskii arkhiv. 2013;85(1):62-65.
      14. Tsukanov V.V., Tret'yakova O.V., Amel'chugova O.S., Kasparov E.V., Rodina D.V., Vasyutin A.V., Butorin N.N., Tonkikh Yu.L. Rasprostranennost' atroficheskogo gastrita tela zheludka u naseleniya g. Krasnoyarska starshe 45 let. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. – 2012. – № 4. – С. 27-31.
      15. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process – First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Research. 1992;52(24):6735–6740.
      16. Polk D.B., Peek R.M.Jr. Helicobacter pylori: gastric cancer and beyond. Nature Reviews Cancer. 2010;10(6):403–414.
      17. Thiel A., Ristimaki A. Gastric cancer: basic aspects. Helicobacter. 2012;17(1):26–29.
      18. Dicksved J., Lindberg M., Rosenquist M., Enroth H., Jansson J.K., Engstrand L. Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls. Journal of Medical Microbiology 2009. 58(4):509–516.
      19. Eun C.S., Kim B.K., Han D.S., Kim S.Y., Kim K.M., Choi B.Y., Song K.S., Kim Y.S., Kim J.F. Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods. Helicobacter. 2014;19(6):407–416.
      20. Yang I., Woltemate S., Piazuelo M.B., Suerbaum S. Different gastric microbiota compositions in two human populations with high and low gastric cancer risk in Colombia. Sci. Rep. 2016;6. – P. 18594.
      21. Dias-Jácome E., Libânio D., Borges-Canha M., Galaghar A., Pimentel-Nunes P. Gastric microbiota and carcinogenesis: the role of non-Helicobacter pyloribacteria – A systematic review. Rev. Esp. Enferm. Dig. 2016;108(9):530-540.
      22. Sugano K., Tack J., Kuipers E. J., Graham D.Y., El-Omar E.M.., Miura S., Haruma K.,Asaka M. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):353-1367.
      23. Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T., Bazzoli, Gasbarrini A., Atherton J., Graham D.Y., Hunt R., Moayyedi P., Rokkas T.,Rugge M., Selgrad M., Suerbaum S., Sugano K., El-Omar E.M. Management of Helicobacter pylori infection-the Maastricht V. Florence Consensus Report. Gut. 2017;66(1):6-30.
      24. Minemura M., Shimizu Y. Gut microbiota and liver diseases. World J Gastroenterol. 2015;21(6):1691-1702.


    Full text is published :
    Tsukanov V.V., Kasparov E.V., Vasyutin A.V., Tonkih Yu.L. THE ROLE OF MICROBIOTA IN THE DEVELOPMENT OF GASTRIC PATHOLOGY. Experimental and Clinical Gastroenterology Journal. 2017;148(12):47-50
    Read & Download full text

    1. Far Eastern state medical University (Khabarovsk, Russian Federation)

    Abstract: The problem of extragastroduodenal manifestations of Helicobacter pylori infection has been studied for more than 20 years. The significance of Helicobacter pyloriin the development of idiopathic thrombocytopenic purpura, iron deficiency anemia and B 12-deficiency anemia, atherosclerosis, obesity, bronchial asthma, Alzheimer’s disease, Parkinson’s disease was reflected in the V Maastricht Consensus. The review presents the latest data on the association of Helicobacter pylori with cardiovascular, neurological, hematological, dermatological diseases, as well as with the development of diabetes mellitus and metabolic syndrome.

      1. Malfertheiner P., Megraud F., O’Morain C.A. et al. Management of Helicobacter pylori infection – the Maastricht V. Florence Consensus Report. Gut. 2017;66(1):6-30.
      2. Burns M., Muthupalani S., Ge Zh. et al. Helicobacter pylori infection induces anemia, depletes serum iron storage, and alters local iron-related and adult brain gene expression in male INS-GAS mice. PLoS One. 2015;10(11):e0142630. doi:10.1371/journal.pone.0142630.
      3. Emiralioglu N., Yenicesu I., Sari S. et al. An insight into the relationships between prohepcidin, iron deficiency anemia, and interleukin-6 values in pediatric Helicobacter pylori gastritis. European Journal of Pediatrics. 2015;174(7):903-910.
      4. Hwang J.J., Lee D.H., Yoon H. et al The effects of Helicobacter pylori eradication therapy for chronic idiopathic thrombocytopenic purpura. Gut and Liver. 2016;10(3):356-361.
      5. Amiri M. Impact of helicobacter pylori eradication therapy on platelet counts in patients with chronic idiopathic thrombocytopenic purpura. Global Journal of Health Science. 2005;8(7):35–40.
      6. Kim H., Lee W.S., Lee K.H. et al. Efficacy of Helicobacter pylori eradication for the 1 line treatment of immune thrombocytopenia patients with moderate thrombocytopenia. Annals of Hematology. 2015;94(5):739–746.
      7. Sun J., Rangan P., Bhat S.S., Liu L. A meta-analysis of the association between Helicobacter pylori infection and risk of coronary heart disease from published prospective studies. Helicobacter. 2016;21(1):11–23.
      8. Matusiak, A., Chałubiński M., Broncel M. et al. Putative consequences of exposure to Helicobacter pyloriinfection in patients with coronary heart disease in terms of humoral immune response and inflammation. Archives of Medical Science. 2016;12(1):45–54.
      9. Niccoli G., Roberto M., D’Amario D. et al. Cytotoxin-associated gene antigen-positive strains of Helicobacter pyloriand recurring acute coronary syndromes. European Heart Journal: Acute Cardiovascular Care. 2015;460(3):721–726.
      10. Lin Y., Obata Y., Kikuchi S. Helicobacter pylori infection and risk of death from cardiovascular disease among the japanese population: a nested case-control study within the JACC study. Journal of Atherosclerosis and Thrombosis. 2015;22(11):1207–1213.
      11. Xu Y., , Wang Q., Liu Y. et al. Association between Helicobacter pylori infection and carotid atherosclerosis in patients with vascular dementia. Journal of the Neurological Sciences. 2016;362:73–77.
      12. Sarıcı S.U., Gursel O., Kurekci E., Kesik V. Anticardiolipin antibodies in children with Helicobacter pylori infection. Helicobacter. 2015;20(6):418–421.
      13. Huang B., Chen Q. Xie et al. CagA-positive Helicobacter pylori strains enhanced coronary atherosclerosis by increasing serum OxLDL and HsCRP in patients with coronary heart disease. Digestive Diseases and Sciences. 2011;(56)1:109–114.
      14. Yan J., Yan J., She Q., Zhang Y. et al. The association between arrhythmia and Helicobacter pylori infection: a meta-analysis of case-control studies. International Journal of Environmental Research and Public Health. 2016;13(11). doi:10.3390/ijerph13111139.
      15. Bua X.L., Yaoa X.Q., Jiaoa S.S. et al. A study on the association between infectious burden and Alzheimer’s disease. European Journal of Neurology. 2015;22(12):1519–1525.
      16. Bua X. L., Bua X.L., Wang X., Xiang Y. The association between infectious burden and Parkinson’s disease: A case-control study. Parkinsonism and Related Disorders. 2015;21(8):877–881.
      17. Wang X.L., Bua X.L., Wang X., Xiang Y. Helicobacter pylori filtrate induces alzheimer-like Tau hyperphosphorylation by activating glycogen synthase kinase-3β. Journal of Alzheimer’s Disease. 2015;43(1):153–165.
      18. Rees K., Rees K., Stowe R., Patel S. et al. Helicobacter pylorieradication for Parkinson’s disease. Cochrane Database of Systematic Reviews. 2011(11).
      19. Jaruvongvanich V., Sanguankeo, S., Jaruvongvanich, Upala S. Association between Helicobacter pylori infection and multiple sclerosis: A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders. 2016;7(3):92–97.
      20. Reibman J., Marmor M., Filner J. et al. Asthma is inversely associated with Helicobacter pylori status in an urban population. PLoS ONE. 2008;3(12) – e4060. doi: 10.1371/journal.pone.0004060.
      21. Chen Y. Inverse associations of Helicobacter pylori with asthma and allergy. Archives of Internal Medicine. 2007;167:821–827.
      22. Engler D. B., Reuterb S., Wijckc Y. et al. Effective treatment of allergic airway inflammation with Helicobacter pylori immunomodulators requires BATF3-dependent dendritic cells and IL-10. PNAS. 2014;111(32):11810–11815.
      23. Wang Y. C., Wang Y.C Lin T.Y., Shang S.T.,Chen H.J., Kao C.H., Wu C.C., Yang T.Y. Helicobacter pylori infection increases the risk of adult-onset asthma: a nationwide cohort study. European Journal of Clinical Microbiology & Infectious Diseases. 2017;36(9):1587–1594. doi:10.1007/s10096–017–2972–1.
      24. Sze M. A., Chen Y.R., Tam S. et al. The relationship between Helicobacter pylori seropositivity and COPD. Thorax. 2015. 70(10):923–929.
      25. Teke T.A., Akyön Y, Yalcin E. et al. Does Helicobacter pylori play a role in the pathogenesis of non-cystic fibrosis bronchiectasis? Pediatrics International. 2016;58(9):894–898.
      26. Kreuter M., Kreuter M., Kirsten D., Bahmer T. et al. Screening for Helicobacter pylori in idiopathic pulmonary fibrosis lung biopsies. Respiration. 2016:91:3–8.
      27. Nakashima S., Kakugawa T., Yura H. et al. Identification of Helicobacter pylori VacA in human lung and its effects on lung cells. Biochemical and Biophysical Research Communications. 2015;460(3):721–726.
      28. Lender N., Talley N.J., Enck P., Haag S., Zipfel S., Morrison M., Holtmann G.J. Review article: associations between Helicobacter pylori and obesity – an ecological study. Alimentary Pharmacology and Therapeutics. 2014;40(1):24–31.
      29. Lane J. A., Murray L.J., Harvey I.M. et al. Randomised clinical trial: Helicobacter pylori eradication is associated with a significantly increased body mass index in a placebo-controlled study. Alimentary Pharmacology & Therapeutics. 2011;33(8):922–929.
      30. Kasai C., Sugimoto K., Moritani I. Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection. Gastroenterology. 2016;119:1–8.
      31. Chen L. W., Chien C. Y., Hsieh C. W. The associations between Helicobacter pylori infection, serum vitamin D, and metabolic syndrome. Medicine. 2016;95(18):1–6.
      32. Dai Y. N., Dai Y.N., Yu W.L., Zhu H. T. et al. Is Helicobacter pylori infection associated with glycemic control in diabetics? World Journal of Gastroenterology. 2015;21(17):5407–5416.
      33. Han X., Li Y., Wang J. et al. Helicobacter pylori infection is associated with type 2 diabetes among a middle- and old-age Chinese population. Diabetes. Metabolism Research and Reviews. 2016;32(1):95–101.
      34. Lebwohl B., Blaser M.J., Ludvigsson J.F. et al. Decreased risk of celiac disease in patients with Helicobacter pylori colonization. American Journal of Epidemiology. 2013;178(12):1721–1730.
      35. Dellon E.S., Peery A.F., Shaheen N.J. et al. Inverse association of esophageal eosinophilia with Helicobacter pylori based on analysis of a US pathology database. Gastroenterology. 2011;141(5):1586–1592.
      36. Rokkas T., Gisbert J.P., Niv Y., O’Morain C. The association between Helicobacter pylori infection and inflammatory bowel disease based on meta-analysis. United European Gastroenterology Journal. 2015;3(6):539–550.
      37. Kim T. J., Sinn D.H., Min Y.W.et al. A cohort study on Helicobacter pylori infection associated with nonalcoholic fatty liver disease. Journal of Gastroenterology. 2017;52(5). doi: 10.1007/s00535–017–1337-y.
      38. Chen C. X., Mao Y.S., Foster P. et al. Possible association between helicobacter pylori infection and non-alcoholic fatty liver disease. Applied Physiology, Nutrition, and Metabolism. 2017;42(3):295–301.
      39. Schulz C., Schütte K., Malfertheiner P. Does H. pylori eradication therapy benefit patients with hepatic encephalopathy? Systematic review. Journal of Clinical Gastroenterology. 2014;48(6):491–499.
      40. Shakouri A., Compalati E., Lang D.M., Khan D.A. Effectiveness of Helicobacter pylori eradication in chronic urticaria: evidence-based analysis using the Grading of Recommendations Assessment, Development, and Evaluation system. Current Opinion in Allergy & Clinical Immunology. 2010;10(4):362–369.
      41. Gu H., Li L., Gu M., G. Zhang G. Association between Helicobacter pylori infection and chronic urticaria: a meta-analysis. Gastroenterology Research and Practice. 2015:2015.
      42. Anwar W., Armstrong B.K., Correa P. et al. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. – 1994;61:1–241.
      43. Leontiadis G. I., Ford A.C., Moayyedi P. Helicobacter pylori infection BMJ Clinical Evidence. 2009:10.406–450.
      44. Zhao Y., Wang X., Wang Y. et al. Helicobacter pylori infection and colorectal carcinoma risk: A meta-analysis. Journal of Cancer Research and Therapeutics. 2016;12(1):15–18.
      45. Rabelo-Goncalves E. M., Sgardioli I.C., Lopes-Cendes I. et al. Improved detection of helicobacter pylori DNA in formalin-fixed paraffin-embedded (FFPE) tissue of patients with hepatocellular carcinoma using laser capture microdissection (LCM). Helicobacter. 2013;18:244–245.
      46. Guo Y., Liu W., Wu J. Helicobacter pylori infection and pancreatic cancer risk: A meta-analysis. Journal of Cancer Research and Therapeutics. 2016;32(3):229–232.


    Full text is published :
    Alekseenko S.A., Koltunov A.S., Koltunov S.S.EXTRAGASTROINTESTINAL MANIFESTATIONS OF HELICOBACTER PYLORI INFECTION. Experimental and Clinical Gastroenterology Journal. 2017;148(12):51-55
    Read & Download full text

    1. Kuban state medical University (Krasnodar, Russian Federation)
    2. Regional clinical hospital № 2 (Krasnodar, Russian Federation)

    Keywords: eosinophilic esophagitis, diagnostics

    Abstract: Eosinophilic esophagitis (EoE) is a rare diagnosed disease characterized by dysphagia symptoms. The lineament of the disease is eosinophilic infiltration of esophageal mucosa. A clinic case of EoE is presented and difficulties of differential diagnostics of EoE and gastro-esophageal reflux disease (GERD) are discussed. EoE is a disease that is similar to GERD in clinic features but different one in pathogenesis. It requires the principal new approach to treatment. Despite the clear differential-diagnostic criteria it should be keep in mind all clinical and histological constellations to exclude GERD, make right conclusion and choose the adequate tactics of treatment.

      1. Atkins D., Kramer R., Capocelli K., Lovell M., Furuta G.T. Eosinophilic esophagitis: the newest esophageal inflammatory disease. Nature Reviews Gastroenterology & Hepatology. 2009;6(5):267-278. doi:10.1038/nrgastro.2009.45
      2. Gonsalves N., Policarpio–Nicolas M., Zhang Q., Rao M.S., Hirano I. Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis. Gastrointestinal Endoscopy. 2006;64(3):313-322.
      3. Dellon E.S., Gibbs W.B., Fritchie K.J., Rubinas T.C., Wilson L.A., Woosley J.T., Shaheen N.J. Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. Clinical Gastroenterology and Hepatology. 2009;7(12):1305-1313.
      4. Liacouras C., Furuta G., Hirano I., Atkins D., Attwood S.E., Bonis P.A., Burks A.W., Chehade M., Collins M.H., Dellon E.S., Dohil R., Falk G.W., Gonsalves N., Gupta S.K., Katzka D.A., Lucendo A.J., Markowitz J.E., Noel R.J., Odze R.D., Putnam P.E., Richter J.E., Romero Y., Ruchelli E., Sampson H.A., Schoepfer A., Shaheen N.J., Sicherer S.H., Spechler S., Spergel J.M., Straumann A., Wershil B.K., Rothenberg M.E., Aceves S.S. Eosinophilic esophagitis: updated consensus recommendations for children and adults. The Journal of Allergy and Clinical Immunology. 2011;128(1):3-20.
      5. Ivashkin V.T., Baranskaya E.K., Kaibysheva V.O. et al. Klinicheskie rekomendatsii po diagnostike i lecheniyu eozinofil'nogo ezofagita. Moscow, 2013. 38 p.
      6. Langdon D. E. Congenital esophageal stenosis, corrugated ringed esophagus, and eosinophilic esophagitis. Am. J. Gastroenterol. 2000;95:2123-2124.
      7. Lim J., Gupta S., Fitzgerald J. et al. White specks in esophageal mucosa: a true endoscopic manifestation of severe eosinophilic esophagitis in children. J. Pediatr. Gastroenterol. Nutr. 2001;33:411.
      8. Krarup A., Villadsen G., Mejlgaard E., Olesen S.S., Drewes A.M.,Funch-Jensen. Acid hypersensitivity in patients with eosinophilic esophagitis. Scandinavian Journal of Gastroenterology. 2010;45(3):273-281.
      9. Markowitz J., Liacouras C. Eosinophilic esophagitis. Gastroenterology Clinics of North America. 2003;32(3):949-966.
      10. Foroutan M., Norouzi A., Molaei M., Mirbagheri S.A., Irvani S., Sadeghi A., Derakhshan F., Tavassoli S., Besharat S., Zali M. Eosinophilic esophagitis in patients with refractory gastroesophageal reflux disease. Digestive Diseases and Science. 2010;55(1):28-31.
      11. Landres R., Kuster G., Strum W. Eosinophilic esophagitis in a patient with vigorous achalasia. Gastroenterology. 1978;74:1298-301.
      12. Prasad G.A., Alexander J.A., Schleck C.D., Zinsmeister A.R., Smyrk T.C., Elias R.M., Locke G.R., Talley N.J. Epidemiology of eosinophilic esophagitis over three decades in Olmsted county, Minnesota. Clin. Gastroenterol. Hepatol. 2009;7(10):1055-1116.
      13. Straumann A., Spichtin H., Bernoulli R. Loosli J., Vögtlin J. Idiopathic eosinophilic esophagitis: a frequently overlooked disease with typical clinical aspects and discrete endoscopic findings (in German). Schweiz. Med. Wochenschr. 1994;Vol.124:1419-1429.
      14. Ahmad M., Soetikno R., Ahmed A. The differential diagnosis of eosinophilic esophagitis. Journal of Clinical Gastroenterology. 2000;30(3):242-244.
      15. Bohm M., Richter J., Kelsen S., Thomas R. Esophageal dilation: simple and effective treatment for adults with eosinophilic esophagitis and esophageal rings and narrowing. Diseses of the Esophagus. 2010;23(5):377-385.
      16. Furuta G. T. Eosinophilic esophagitis: Update on clinicopathological manifestations and pathophysiology. Curr. Opin. Gastroenterol. 2011;27(4):383-388.


    Full text is published:
    Serikova S.N., Korochanskaya N.V. DIFFICULTIES OF DIFFERENTIAL DIAGNOSTICS OF EOSINOPHILIC ESOPFAGITIS AND GASTRO-ESOPHAGEAL REFLUX DISEASE. Experimental and Clinical Gastroenterology Journal. 2017;148(12):56-59
    Read & Download full text

    1. Smolensk State Medical University (Smolensk, Russian Federation)

    Keywords: Helicobacter pylori, antimicrobial resistance, clarithromycin, metronidazole

    Abstract: The article reviews current approaches to the choice of H. pylori eradication therapy depending on the antimicrobial susceptibility patters of this pathogen to the major components of eradication treatment. First and second line eradication therapy in patients with intolerance to antimicrobials are also discussed, as well as the options for the third line therapy in case of unknown H. pylori susceptibility patterns.

      1. Sugano K., Tack J., Kuipers E.J., Graham D.Y., El-Omar E.M., Miura S., Haruma K., Asaka M., Uemura N., Malfertheiner P. Kyoto global consensus report on Helicobacter pylorigastritis. Gut. 2015;64:1-15. doi:10.1136/gutjnl-2015–309252.
      2. Malfertheiner P., Megraud F., O’Morain C. et al. Management of Helicobacter pylori infection – Maastricht V / Florence consensus report. Gut. 2016;(1):1-25. doi:10.1136/gutjnl-2016–312288.
      3. Graham D.Y., Fischbach L. Helicobacter pyloritreatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143-53.
      4. Horiki N., Omata F., Uemura M., Suzuki S., Ishii N., Iizuka Y., Fukuda K., Fujita Y., Katsurahara M., Ito T., Cesar G.E., Imoto I., Takei Y. Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter. 2009;14:86-90.
      5. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53:1374-84.
      6. Cun S., Li H., Ge R., Lin M.C., Sun H. A histidine-rich and cysteine-rich metal-binding domain at the C terminus of heat shock protein A from Helicobacter pylori: implication for nickel homeostasis and bismuth susceptibility. Journal of Biological Chemistry. 2008;283(22):15142-51. doi:10.1074/jbc.M800591200
      7. Graham D.Y., Lee Y.C., Wu M.S. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clinical Gastroenterology and Hepatology. 2014;12(2):177-86.
      8. Reza Ghotaslou, Hamed Ebrahimzadeh Leylabadlo, Yalda Mohammadzadeh Asl. Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review. World Journal of Methodology. 2015;5(3):164-74.
      9. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, Ierardi E, Zullo A. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010;19:409-414.
      10. Nishizawa T., Suzuki H., Matsuzaki J., Muraoka H., Tsugawa H., Hirata K., Hibi T. Helicobacter pylori resistance to rifabutin in the last 7 years. Antimicrobial Agents and Chemother. 2011;55(11):5374-75.
      11. Pozdeev O.K., Morozova L.G., Pozdeeva A.O., Valeeva Yu. V., Gulyaev P.E. Monitoring pervichnoi antibiotikorezistentnosti shtammov Helicobacter pylori, vydelennykh v respublike Tatarstan v 2008–2013 gg. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya – Clinical Microbiology and antimicrobial Chemotherapy. 2016;18(2):146-51.
      12. Dekhnich N.N., Kostyakova E.A., Punin A.A., Alimov A.V., Ivanchik N.V., Kozlov R.S. Antibiotikorezistentnost' H. pylori: rezul'taty mikrobiologicheskogo regional'nogo issledovaniya. Rosciiskii zhurnal gastroenterologii, gepatologii, koloproktologii. – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2011;21(2):37-42.
      13. Dekhnich N.N., Ivanchik N.V., Kozlov R.S., Alimov A.V., Luk'yanova A.V., Nagaeva O.A., Steshits A.S., Bruk P. G. Chuvstvitel'nost' shtammov H. Pylori k antimikrobnym preparatam v g. Smolenske v 2015–2016 gg. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;6:24-31.
      14. Sablin O.A., Mikhailov N.V., Yurin M.V., Il'chishina T.A., Kondrashin A.S., Kobiashvili M.G., Mikhailova I.A., Svarval' A.V., Zhibrun A.B. Pervichnaya rezistentnost' Helicobacter pylori k antibiotikam v Sankt-Peterburge. Eksperimental'naya i klinicheskaya farmakologiya. 2012;(8):18–23.
      15. Simanenkov V. I., Zakharova N. V., Zhebrun A. B., Svarval' A. V., Savilova I. V., Ferman R. S. Rezistentnost' Helicobacter pylori k antimikrobnym preparatam po rezul'tatam bakteriologicheskogo testirovaniya. Lechashchii vrach. 2015;(4):91–5.
      16. Lazebnik L.B., Belousova N.L., Bordin D.S., Mikheeva O.M., Dubtsova E.A., Vorob'eva N.N., Zelenikin S.A. Rezistentnost' Helicobacter pylori k klaritromitsinu v Moskve i propolis kak sredstvo, povyshayushchee effektivnost' eradikatsii. Eksperimental'naya i klinicheskaya farmakologiya. 2012;(8):10–14.
      17. Kornienko E.A., Suvorov A.N., Tkachenko E.A., Uspenskii Yu.P., Baryshnikova N.V. Kriticheskii rost rezistentnosti Helicobacter pylori k klaritromitsinu v pediatricheskoi i vzrosloi gastroenterologicheskoi praktike. Spravochnik poliklinicheskogo vracha. 2010;(12):54–56.
      18. Bokarev A.A., Perfilova K.M., et al. Ustoichivost' Helicobacter pylori k makrolidam u bol'nykh c N. pylori-pozitivnoi gastroduodenal'noi patologiei. Materialy II Ezhegodnogo Vserossiiskogo Kongressa po infektsionnym boleznyam. Moskva, 29-31 marta 2010 g.
      19. Osipenko M.F., Bikbulatova E.A., Shakalite Yu.D., Chernova L.N. Rezistentnost' Helicobacter pylori k klaritromitsinu v No vosibirske. Российский журнал гастроэнтерологии, гепатологии и колопроктологии. – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2012;22(5)(прил. 40):36.
      20. Ivashkin V.T., Maev I.V., Lapina T.L., Sheptulin A.A., et al . Rekomendatsii Rossiiskoi Gastroenterologicheskoi Assotsiatsii po diagnostike i lecheniyu infektsii Helicobacter pylori u vzroslykh. Российский журнал гастроэнторологии, гепатологии, колопроктологии. – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2012;22(1):87-89.


    Full text is published :
    Dekhnich N.N., Ivanchik N.V., Prischepova E.A., Kozlov R.S. THE CHOOSE HELICOBACTER PYLORIERADICATION THERAPY IN ADULTS. Experimental and Clinical Gastroenterology Journal. 2017;148(12):60-66.
    Read & Download full text

    1. North-Western State Medical University n. a. I. I. Mechnikov

    Keywords: candidiasis, therapy of H. pylori proton pump inhibitors

    Abstract: Pathogenesis of candidiasis of the digestive tract is characterized by sequential passage of the mushrooms following stages - adhesion, invasion, candidemia and visceral lesions. In the first stage, the micromycetes adhere to the epithelial cells of any portion of the mucous membrane. Further, defects in the system of resistance allows the micromycetes through transformation in pseudomycelia implemented (to invazirujutsja) in the mucous membrane and underlying tissues. Cytopenia - a crucial factor that allows invazirujutsja mushrooms to reach the walls of blood vessels, to destroy it, and to circulate in the bloodstream (this step is called candidemia). In the absence of adequate therapy in candidemia leads to the formation of foci of invasive candidiasis in visceral organs, most often in the liver and the spleen, the lungs, the Central nervous system. Introduction fungi of the genus Candida commonly occurs in areas of the mucous membrane, presents a multilayered epithelium (mouth, esophagus) and significantly less in single-layer epithelium (stomach, intestines). Proton pump inhibitors, reducing the acidity of the upper gastrointestinal tract and antibiotics killing the natural competitors of micromycetes of bacteria that can cause candidiasis, especially in patients at risk. The data on etiology, clinical features, diagnostic criteria and treatment of the most common oral lesions..

      1. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report. Article in Gut · October 2016, DOI: 10.1136/gutjnl-2016-312288
      2. Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015;64:1353-67.
      3. Hunt RH, Camilleri M, Crowe SE, et al. The stomach in health and disease. Gut, 2015;64:1650-68.
      4. Хмельницкий О. К. О кандидозе слизистых оболочек. // Архив патологии, 2000. - Том 62, N 6, С 3-10.
      5. Jobst D., Kraft K. Candida species in stool, symptoms and complaints in general practice - a cross-sectional study of 308 outpatients. Mycoses, 2006, 49, 415-420.
      6. Hube B. Candida albicans secreted aspartyl proteinases. // Curr Top Med Mycol. - 1996. - Vol.7(1). - P. 55-69.
      7. Хмельницкий О. К., Хмельницкая Н. М. Патоморфология микозов человека. - Спб.: Издательский дом СПбМАПО, 2005. - 432 с., ил.
      8. Климко Н. Н. Микозы: диагностика и лечение. Руководство для врачей. 3-е изд. Перераб. И доп. - М.: Фармтек, 2017. - 272 с.


    Full text is published :
    Shevyakov M.A. Melekhina Yu.E., Klimko N.N. CANDIDIASIS OF MUCOUS MEMBRANES AS A COMPLICATION OF THE COURSE OF HELICOBACTER-ERADICATION. Experimental and Clinical Gastroenterology Journal. 2017;148(12):67-71.
    Read & Download full text

    1. Clinic № 1 of Department for presidential Affairs of RF

    Keywords: Helicobacter pylori,gastro,schemes of eradication,H. pylori therapy,food allergies,intolerance of antibiotics,antibiotic resistance

    Abstract: The study of the pathogenic properties of Helicobacter pylori have shown that this microorganism is able to damage the mucous membrane of the stomach and duodenum may contribute to the protracted course of gastroduodenitis, increases the frequency of relapses. This has changed approaches to the treatment and especially the prevention of recurrence. Developed and widely used in eradication schemes with the prolonged use of multiple antibiotics, which often leads to serious complications. In this article, we analyzed a number of controversial issues related to the study of HP-associated pathology.

      1. Аруин Л. И., Григорьев П. Я., Яковенко Э. П. Хронический гастрит. Амстердам, 1993. 362 с.
      2. Домарадский И. В. Вопросы патогенности Helicobacter pylori // Эпидемиол. и инфекц. болезни. 2001. № 2. С. 45-47.
      3. Дрынов И. Д., Малышев Н. А., Диденко Л. В., Дрынов Г. И. Подходы к терапии хронических бактериальных инфекций // Москва., «ОЛЛ-БИ ПРИНТ»., Монография. 2011. 165с.
      4. Крылов Н. Н. Проблемы, которые не могут не волновать: утопии и реалии современного учения о язвенной болезни. Вестник хирургической гастроэнтерологии. - 2007. - № 1. - с. 25-30.
      5. Чернин В. В., Бондаренко В. М., Базлов С. Н. Место H. pylori и дисбактериоза гастродуоденальной зоны в этиологии и патогенезе ЯБ и ХГ. Сб. тезисов ХХХIX сессия «Мультидисциплинарный подход к гастроэнтерологическим проблемам». 2013. 5-6 марта. С. 49-50.
      6. Циммерман Я. С. Гастродуоденальная патология и Helicobacter pylori // Клин. фармакол. и терапия. 1999. № 2.
      7. Шептулин А. А. Современный алгоритм лечения язвенной болезни. Клин. медицина 2004; 82 (I): 57-60.
      8. Ando T., Perez-Perez G. I., Kusugami K., Blazer M. J. et al. Anti-CagA immunoglobulin G responses correlate with interleukin-8 induction in human gastric mucosal biopsy culture // Clin and Diagn Labor Immunol. 2000. Vol. 7. № 5. P. 803-809.
      9. Coelho L. G. V., Martins G. М., Passes М. C. F., Bueno М. L. et al. Once-daily, low-cost, highly effective HP treatment to family members of gastric cancer patients. Aliment. Pharmacol. Ther. 2003
      10. Bamford K. B., Fan X., Crowe S. E. et al. Lymphocytes in the human gastric mucosa during H.pylori have a T-helper cells 1 phenotype // Gastroent. 1998. № 114. P. 482-492.
      11. Higuchi K., Fujiwara Y., Tominaga К. et al. Is eradication sufficient to heal gastric ulcer in patients infected with Helicobacter pylori? A randomized, controlled, prospective study. Aliment. Pharmacol. Ther. 2003; 17: 111-117.
      12. Blazer M. J. Helicobacter pylori and gastric diseases // Brit. Med. J. 1998. Spl 316. P. 1507-1510.
      13. Camorlinga-Ponce M., Torres J., Perez-Perez J. et al. Validation of a serological test for the diagnosis of Helicobacter pylori infection and the immune response to urease and CagA in children // Amer. J. Gastroent. 1998. Aug 93 (8). P. 1264-1270.
      14. Chavez E., Sanmiento F., Lopez M. et al. Interleukin-8 levels in gastric biopsies of children colonized by Helicobacter pylori // Rev. Med. Clin. 1998. Feb 126 (2). P. 139-142.
      15. Дрынов Г. И., Ушакова Д. В., Сластушенская И. Е., Иванюшина О. К. «Патогенез аллергических заболеваний у пациентов с патологией пищеварительного тракта», Кремлевская медицина № 2, 2014 г., с. 139-143


    Full text is published :
    Drynov G.A.,Ivaniushina D.C.,Mikhalina I.A., THE ROLE OF Helicobacter pylori INFESTATION IN ALLERGIC PATHOLOGY: DISCUSSION QUESTIONS. Experimental and Clinical Gastroenterology Journal. 2017;148(12):72-75.
    Read & Download full text

    1. Military Medical Academy (Saint Petersburg, Russian Federation)

    Keywords: a chronic gastritis, H.pylori, the morphogenesis, recombinations, the new concept

    Abstract: In article logic contradictions of the developed representations about the nature of a chronic gastritis, modern difficulties and errors of its diagnostics are discussed, attempt becomes is critical to estimate a real role of infection H.pylori. On the basis of own long-term clinical and morphological experience the author results a number of the arguments testifying about multifactorial of damage of a mucous membrane of a stomach, but, during too time, about universality of the most basic sides of morphogenesis this pathology. Instead of the cascade theory assuming sequence of stages of morphogenesis, it is offered new (hierarchical, combinational) the concept of formation of a chronic gastritis, including as precancer condition.

      1. Tsimmerman Ya.S. Stoikie zabluzhdeniya sovremennoi gastroenterologii. Klinicheskaya farmakologiya i terapiya. 2016;25(5):5-12.
      2. Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J. P., Kuipers E. J., Axon A. T., Bazzoli F., Gasbarrini A., Atherton J., Graham D. Y., Hunt R., Moayyedi P., Rokkas T., Rugge M., Selgrad M., Suerbaum S., Sugano K., ElOmar E. M. Management of Helicobacter pylori infection – the Maastricht V / Florence Consensus Report. Gut. 2016. doi:10.1136/gutjnl-2016–312288.
      3. Захарова Н.В., Бакулин И.Г., Симаненков В.И., Маслыгина А.А. Обзор рекомендаций пятого Маастрихтского/Флорентийского консенсуса по диагностике и лечению инфекции Helicobacter pylori. Фарматека. 2016,s5-16:8-26.
      4. Sugano K., Tack J., Kuipers E.J., Graham D.Y., El-Omar E.M., Miura S., Haruma K., Asaka M., Uemura N., Malfertheiner P. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353-1367.
      5. Кононов А.В. Маастрихт-4. Стратегия профилактики рака желудка: кому, как и когда. Доклад. Интернет сессия. 12 марта 2014 г.
      6. Саркисов Д. С. Клинико-анатомическое направление на современном этапе развития медицины. Клиническая медицина, 1990, том 68, № 3, сс. 3–7. .
      7. Berlin L.B., Lisochkin B.G., Safonov A.G., Uspenskii V.M. Atlas patologicheskoi gistologii slizistoi obolochki zheludka i dvenadtsatiperstnoi kishki. Leningrad, Nauka, 1975. 165 p.
      8. Dorofeev G.I., Uspenskii V.M. Gastroduodenal'nye zabolevaniya v molodom vozraste. Leningrad, Meditsina, 1984. 144 p.
      9. Uspenskii V.M. Funktsional'naya morfologiya slizistoi obolochki zheludka. Leningrad, Nauka, 1986. 292 p.
      10. Golofeevskii V.Yu., Fomichev A.V., Khalimov Yu.Sh., Malysheva E.V. Endoskopicheskie i morfologicheskie osobennosti patologii zheludka i dvenadtsatiperstnoi kishki u lits, zanyatykh na rabotakh s fosfororganicheskimi soedineniyami. Medline.ru: biomeditsinskii zhurnal. 2014:15:605-619.
      11. Rudoi A.S., Letkovskaya T.A., Uryvaev A.M., Reutskii I.P. Rol' TGFβinduktsii i gastrointestinal'nykh miofibroblastov v patomorfogeneze khronicheskogo gastrita u patsientov s sindromom Marfana i marfanopodobnymi sostoyaniyami. Eksperimental'naya i klinicheskaya gastroenterologiya – Experimental and Clinical Gastroenterology Journal. 2016;130(6):14-18.
      12. Golofeevskii V. Yu. Vvedenie v klinicheskuyu morfologiyu zheludka i dvenadtsatiperstnoi kishki. Saint Petersburg, Foliant, 2005. 112 p.
      13. Golofeevskii V.Yu. Obshchie zakonomernosti patomorfogeneza khronicheskogo gastrita i kritika teorii «kaskada Korrea». Novye Sankt-Peterburgskie vrachebnye vedomosti. 2016(4):18-23.
      14. Golofeevskii V.Yu., Pavlovich I.M. Khronicheskii gastrit: vazhneishie voprosy diagnostiki. Novye Sankt-Peterburgskie vrachebnye vedomosti. 2005;4:44-48.
      15. Correa P. The biological model of gastric carcinogenesis. JARC Sci. Publ. 2004;157:301-310.
      16. Pal'tsyn A.A. K 85-letiyu so dnya rozhdeniya akademika RAMN D.S. Sarkisova. Patogenez. 2011;9(1):71-80.


    Full text is published :
    Golofeevskii V.Yu. Reflections about the nature and general pattern of morphogenesis a chronic gastritis. Experimental and Clinical Gastroenterology Journal. 2017;148(12):76-81
    Read & Download full text

    1. Institute of Poliomyelites & viral Encephalitides (Moscow, Russian Federation)

    Keywords: Helicobacter pylori, eradication, chronic gastritis, peptic ulcer disease

    Abstract: A detailed critical analysis of the “Treatment of H. pylori infection” from all Maastricht agreements is presented in the dynamics of their improvement since 1996. It is shown that no significant changes occurred in these recommendations in either drugs used for eradication therapy, either in regimens treatment or in its results during the 20-year period. It is offered to refuse completely to use antibiotics that have been discredited (clarithromycin, metronidazole, etc.) in favor of using bactericidal preparations. It is necessary to radically review the procedure of treatment and switch from tablets to “liquid” technology, which allows acting directly on the infection throughout the surface of the gastric mucosa.

      1. NIH consensus development panel on Helicobacter pyloriin peptic ulcer disease. JAMA. 1994;272:65-69.
      2. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut. 1997;41(1):8-13.
      3. Noach L. A. Helicobacter pyloriinfection. Aspects of pathogenesis and therapy. Amsterdam, 1993. 168 p.
      4. Malfertheiner P., Mégrau d F., O’Morain C., Hungin A. P. S., Jones R., Axon A., Graham D. Y., Tytgat G. Current concepts in the management of Helicobacter pylori infection – The Maastricht 2–2000 Consensus Report. Alimentary Pharmacology and Therapeutics. 2002;16(2):167-180.
      5. Malfertheiner P., Megraud F., O’Morain C., Bazzoli F., El-Omar E., Graham D., Hunt R., Rokkas T., Vakil N., Kuipers E.J. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56(6):772-781.
      6. Malfertheiner P., Megraud F., O’Morain C.A., Atherton J., Axon A.T.R., Bazzoli F., Gensini G.F., Gisbert J.P., Graham D., Rokkas T., El-Omar E., Kuipers E.J. Management of Helicobacter pylori infection – the Maastricht IV / Florence Consensus Report. Gut. 2012;61(5):646-664.
      7. Graham D. Y., Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143-1153
      8. Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T., Bazzoli F., Gasbarrini A., Atherton J., Graham D.Y., Hunt R., Moayyedi P., Rokkas T., Rugge M., Selgrad M., Suerbaum S., Sugano K., El-Omar E.M. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30.
      9. Kaneko E., Hoshihara Y., Sakaki N., Harasawa S., Ashida K., Asaka M., Asaki S., Nakamura T., Kobayashi K., Kajiyama G., Ogawa N., Yao T., Muto Y., Nakazawa S., Takemoto T. Peptic ulcer recurrence during maintenance therapy with H2-receptor antagonist following first-line therapy with proton pump inhibitor. Journal of Gastroenterology. 2000;35(11):824-831.
      10. Schwartz H., Krause R., Sahba B., Herber M., Weissfeld A., Rose P., Siepman N., Freston J. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, claritromycin, and/or amoxicillin in different dosing regimens. The American Journal of Gastroenterology. 1998;93(4):584-90.
      11. Isakov V.A., Domoradskii I.V. Khelikobakterioz. Moscow, Medpraktika-M. 2003. 412 p.
      12. Khomeriki S.G., Khomeriki N.M. Skrytye aspekty klinicheskogo primeneniya N2-blokatorov. Farmateka. 2002:60(9):9-16.
      13. Pasechnikov V.D., Ivashkin V.T., Chukov S.Z. Ingibitory protonnoi pompy v terapii predrakovykh zabolevanii pishchevoda […].Profilaktika i lechenie khronicheskikh zabolevanii verkhnikh otdelov zheludochno-kishechnogo trakta. Moscow, MEDpress-inform, 2002. pp. 96-124.
      14. Pimanov S.I. Ezofagit, gastrit i yazvennaya bolezn'. Moscow, Meditsinskaya kniga, Nizhny Novgorod, NGMA, 2000. 378 p.
      15. Khomeriki N.M., Khomeriki S.G. Opyt primeneniya chetyrekhkomponentnykh lekarstvennykh skhem, otlichnykh ot standartnoi kvadroterapii, pri lechenii khelikobakternoi infektsii. Rossiiskii zhurnal gatroenterologii, gepatologii i koloproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2001;11(2)Supp. 13:103-105.
      16. Khomeriki N.M., Khomeriki S.G. Chetyrekhkomponentnye skhemy v lechenii khelikobakternoi infektsii: eradikatsiya bez sanatsii. Farmateka. 2004;90(13):19-22.
      17. Graham D. Y., Osato M.S., Hoffman J., Opekun A.R., Anderson S.Y., Kwon D.H., El-Zimaity H.M.T. Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Alimentary Pharmacology and Therapeutics. 2000;14(6):745-750.
      18. Gal'perin Yu.M., Lazarev P.I. Pishchevarenie i gomeostaz. Moscow, Nauka, 1986. 304 p.
      19. Krivova N.A., Dambaev G.Ts., Khitrikheev V.E. Nadepitelial'nyi slizistyi sloi zheludochno-kishechnogo trakta i ego funktsional'noe znachenie. Tomsk, 2002. 315 p.
      20. Endo H., Yoshida H., Ohmi N., Higuchi S. Effects of lansoprazole and amoxicillin on uptake of [14C] clarithromycin into gastric tissue in rats. Antimicrobial Agents and Chemotherapy. 2001;45(12):3451-3455.
      21. Leonova M.V., Belousov Yu.B. N2-blokatory v gastroenterologicheskoi praktike. Moscow, Gedeon Rikhter, 1996. 62 p.
      22. Morozov I.A., Lukina E.V., Lopatina I.V., Grinberg A.A. Dinamika reparatsii yazvennykh defektov 12-perstnoi kishki posle krovotecheniya […]. Helicobacter pylori: revolyutsiya v gastroenterologii. Moscow, Tempus, 1999. pp. 88-97.
      23. Khomeriki S.G., Khomeriki N.M. Skrytye aspekty klinicheskogo primeneniya N2-blokatorov. Farmateka. 2002;60(9):9-16.
      24. Khomeriki S.G., Zhukhovitsky V.G., Khomeriki N.M., Kubatiev A.A. Detection of oxygen free radicals in the bacterial suspension of H.pylori. Mechanisms of activation and suppression. Gut. 2000;47(Suppl.1):A7.
      25. Morozov I.A. Strukturnye aspekty mekhanizma deistviya blokatorov N/K-ATFazy na parietal'nuyu kletku pri lechenii Nr-assotsiirovannykh zabolevanii. Rossiiskii zhurnal gastroenterologii, gepatologii i koloproktologii. – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2001;11(2)(Supp.13):68-70.
      26. Morozov I.A., Nikonov E.L., Miller D.A. New liquid method for Helicobacter pylori eradication. Multicenter study. Helicobacter. 2004;9(5):578-579.
      27. Morozov I.A., Nikonov E.L., Miller D.A. Strukturno-funktsional'noe obosnovanie optimal'nykh uslovii provedeniya eradikatsii Helicobacter pylori v zheludke. Dokazatel'naya gastroenterologiya. 2012;1(2):63-67.
      28. Morozov I.A. Effektivnaya tekhnologiya eradikatsii infektsii Helicobacter pylori v zheludke. Poliklinika. 2015;1(1):29-32.


    Full text is published :
    Morozov I.A. How to break the deadlock of Maastricht? Experimental and Clinical Gastroenterology Journal. 2017;148(12):82-88.
    Read & Download full text

    1. Sechenov First Moscow state medical university of the Russian federation Ministry of Health (Moscow, Russian Federation)
    2. Chuvash State University named after I.N. Ulyanov (Cheboksary, Russian Federation )

    Keywords: gastric ulcer, duodenal ulcer, neurogenic, genetic factors, neurosis, Helicobacter pylori

    Abstract: Purpose of the study . To develop the theory of the etiology of the author of the pathogenesis of peptic ulcer disease. Materials and Methods: In order to develop the author’s views on the etiology and pathogenesis of peptic ulcer treated with about 50 different publications and analyzed the results of their own research. Results. Therefore, genetic theory of neurogenic etiology and pathogenesis of gastric ulcer and duodenal ulcer 12 highly optimized explain causal relationships ulcer patient, allowing variations in the prevalence or otherwise of neurosis factor or local genetic factors. However, obviously other things that only a combination of neurogenic factor genetically altered reactivity of the gastroduodenal system (the presence of the target organ) causes chronic ulcers. Developed-tannaya our theory of peptic ulcer disease, a disease related to psychosomatic pathology allows to develop effective therapies including drugs with psihokorregiruyuschim action.

      1. Litvitskii P.F. Patofiziologiya. Tom 1. Uchebnik dlya vuzov. Moscow, GEOTAR–MED, 2002. 731 p.
      2. Ivashkin V.T., Rapoport S.I. Reshenie kollegii MZ – put' k resheniyu aktual'nykh zadach gastroenterologii. Rossiiskii zhurnal gatroenterologii, gepatologii i koloproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology 2004;14(5, prilozhenie 23):30 .
      3. Kirilenko T.B., Kirilenko M.G. Vremennaya netrudosposobnost' bol'nykh yazvennoi bolezn'yu. Zdravookhranenie RSFSR. 1989;1:23-26.
      4. Soshina A.A., Sergeeva V.V., Zinyaeva T.V. Osobennosti klinicheskoi kartiny i prognoz u patsientov, osvidetel'stvovannykh v byuro mediko-sotsial'noi ekspertizy v svyazi s yazvennoi bolezn'yu zheludka i dvenadtsatiperstnoi kishki. Kazanskii meditsinskii zhurnal. 2013;94(1):124-127.
      5. Kolosov A.S., Mil'chakov D.E. Ekonomicheskaya tselesoobraznost' pravil'nogo pitaniya v formate profilaktiki yazvennoi bolezni na primere goroda Kirova. Mezhdunarodnyi nauchno-issledovatel'skii zhurnal. 2016:5(5):150-152.
      6. Boger M.M. Yazvennaya bolezn'. Novosibirsk, Nauka, 1986. 256 p.
      7. Vasilenko V.Kh., Grebenev A.L., Sheptulin A.A. Yazvennaya bolezn'. Moscow, Meditsina, 1987. 288 p.
      8. Piper D., Hent I., Heap T. The healing rate of chronic gastric ulcer in patients admitted to hospital. Scandinavian Journal of Gastroenterology. 1980;15(1):113-117.
      9. Golikov S.N., Dolgo-Saburov V.B., Elaev N.R. Kuleshov V.I. Kholinergicheskaya regulyatsiya biokhimicheskikh sistem kletki. Moscow, Meditsina, 1985. 319 p.
      10. Orbeli L.A. Lektsii po fiziologii nervnoi sistemy. Moscow, Narkomzdrav SSSR, Leningrad, 1938. 312 p.
      11. Анохин П.К. Очерки по физиологии функциональных систем. Moscow, Meditsina, 1975. 447 p.
      12. Baranova M.N., Chernosvitov E.V. Klinicheskie osobennosti nevrozopodobnykh sostoyanii pri razlichnykh nevroticheskikh zabolevaniyakh. Tbilisi, 1990. 235 p.
      13. Kryzhanovskii G.N. Vvedenie v obshchuyu patofiziologiyu. Moscow, Nauka. 2000. 71 p.
      14. ……. (Russ ed.: Polak D.M., Blum S.R., Rait N.A., Batler A.G. Fiziologiya i patofiziologiya zheludochno-kishechnogo trakta. Moscow, 1989. 320 p.).
      15. Sonnenberg A., Muller-Lisner S. Predicton of duodenal ulcer nealding a relapse. Gastroenterology. 1981;81(5):1061-1067.
      16. Loginov A.S., Arbuzov V.G. Sekretsiya kortizola i gormona rosta u bol'nykh yazvennoi bolezni zheludka i 12-perstnoi kishki. Ter. arkhiv. 1988;2:15-17.
      17. Butov M.A. Ob etiologii i patogeneze yazvennoi bolezni. Gastroenterologiya. 2003;5:5-9.
      18. Gorshkov A.N., Byakov M.Yu., Ivanchenko T.V. Chastota infitsirovannosti helicobacter pylori pri erozivno-yazvennykh porazheniya zheludka i dvenadtsatiperstnoi kishki. Rossiiskii zhurnal gatroenterologii, gepatologii i koloproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2004;14(5, prilozhenie 23):27 .
      19. Zhernakova N.I. Klinicheskaya neiroimmunoendokrinologiya yazvennoi bolezni u lyudei pozhilogo vozrasta. Rossiiskii zhurnal gatroenterologii, gepatologii i koloproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2013;23(2):88-89.
      20. Kokurkin G.V., Ivanov L.N., Semenov V.D. et al. Reaktivnost' organizma pri vozdeistvii lazerokunturoi na zazhivlenie gastroduodenal'nykh yazv [… ]. Tez. I s"ezda immunologov i allergologov Chuvashii, «Nauchno-prakticheskie aspekty sovremennoi immunologii i allergologii». Cheboksary, 1991. 60 p.
      21. Malfertheiner P., Megraud F., O’Morain C. et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Concensus Report. Gut. 2007;56:772-781.
      22. Ivanov L.N., Kokurkin G.V. Vzglyad na etiologiyu yazvennoi bolezni zheludka [… ]. Materialy 3-i resp. konf. khirurgov Chuvashskoi SSR «Aktual'nye voprosy khirurgii yazvennoi bolezni zheludka i 12-perstnoi kishki». Cheboksary, 1992. pp. 6-7.
      23. Ivanov L.N., Kolotilova M.L. Nevrogennye i geneticheskie prichiny i mekhanizmy razvitiya yazvennoi bolezni. Eksperimental'naya i klinicheskaya gastroenterologiya – Experimental and Clinical Gastroenterology Journal. 2005;4:13-18.
      24. Grigor'ev P.A. Yazvennaya bolezn' zheludka i 12-perstnoi kishki. Moscow, 1986. 222 p.
      25. Zagromova T.A., Akbasheva O.E., Tsygol'nik M.D. Konstitutsional'nye razlichiya v aktivnosti proteinaz i ikh ingibitorov pri yazvennoi bolezni. Rossiiskii zhurnal gatroenterologii, gepatologii, koloproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2004;14(5, prilozhenie 23):29.
      26. Chernin V.V. Yazvennaya bolez. Tver, RITs TGMA, 2000. 287 p.
      27. Chernin V.V. Narusheniya neiroendokrinnoi regulyatsii v patogeneze yazvennoi bolezni i puti ikh korrektsii. Mat. IX s"ezda nauchnogo obshchestva gastroenterologov Rossii. Prilozhenie № 1 k zhurnalu Eksperimental'naya i klinicheskaya gastroenterologiya. 2009;2:111-112.
      28. Maslova O.A. Klinika-statisticheskoe issledovanie rassprostranennosti yazvennoi bolezni zheludka i dvenadtsati-perstnoi kishki i taktika ee lecheniya. Rossiiskii zhurnal gastroentrologii, gepotologii, koloproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology 19(1):9-90
      29. Belova O.L., Belova I.M. Helicobacter pylori uskoryaet protsess rubtsevaniya yazvy slizistoi obolochki zheludka i dvenadtsatiperstnoi kishki. Rossiiskii zhurnal Gastroenterologii, Gepatologii, Koloproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2004;14(5, prilozhenie 23):65 .
      30. Bazlov S.N., Egorova E.N. Primenenie bifiliza v lechenii retsidiva yazvennoi bolezni. Rossiiskii zhurnal Gastroenterologii, Gepatologii, Koloproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2004;14(5, prilozhenie 23):20 .
      31. Maev I.V., Dicheva D.T., Petrova E.G. Issledovanie osobennosti psikhologicheskogo statusa u bol'nykh yazvennoi bolezn'yu. Rossiiskii zhurnal Gastroenterologii, Gepatologii, Koloproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. (2005;15(5, Prilozhenie 26):31.
      32. Shirmer B.D., Scott-Jones R. Peptic ulcer disase. Invest. Radiol. 1987;22:437-446.
      33. Gel'fand B.R., Gur'yanov V.A. Martynov A.N. i dr. Profilaktika stress-povrezhdeniy zheludochno-kishechnogo trakta u bol'nykh v klinicheskikh sostoyaniyakh. Consilium medicum. 2005 ;7(6):464-467.
      34. Sokolova G.N., Komarov B.D., Potapova V.B. et al. Lechenie yazvennoi bolezni zheludka u lits pozhilogo vozrasta [… ]. Tezisy V s"ezda Nauchnogo obshchestva gastroenterologov Rossii. Mosscow, 2005. pp. 157-158.
      35. Osadchuk M.A., Osadchuk M.M. Rol' epiteliotsitov, sekretiruyushchikh sosudistyi endotelial'nyi faktor rosta, pankreaticheskii polipeptid i glyukagon v ul'tserogeneze. Rossiiskii zhurnal Gastroenterologii, Gepatologii, Koloproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology 2013;23(5, prilozhenie 42):87 .
      36. Sipponen, P. Peptic uler disease. Gastointetestinal and oesophageal pathology. London, Churchill Livingston, 1995. pp. 512-523.
      37. Sklyanskaya O.A. Bolezni organov pishchevaritel'noi sistemy: klassifikatsiya. Bolezni zheludka. Gastrit. Yazvennaya bolezn' [… ]. Patologiya (Kurs lektsii). Moscow, Meditsina, 2007. pp. 345-362.
      38. Osadchuk M.A., Kireeva N.V., Islamova E.A. Yazvennaya bolezn' dvenadtsatiperstnoi kishki razlichnykh vozrastnykh grupp: rol' diffuznoi neiroendokrinnoi sistemy v ul'tserogeneze. Rossiiskii zhurnal Gastroenterologii, Gepatologii, Koloproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(5, prilozhenie 48):25(86 ).


    Full text is published :
    Kolotilova M.L., Ivanov L.N. Neurogenic-Genetic Factor Of Etiology And Pathogenesis Of Ulcer Disease. Experimental and Clinical Gastroenterology Journal. 2017;148(12):89-97
    Read & Download full text

    1. Moscow state medical- dentistry University n. a. A.I. Evdokimov (Moscow, Russian Federation)
    2. North-Western State Medical University n. a. I.I. Mechnikov (Saint Petersburg, Russian Federation)

    Keywords: fibrosis, liver, Laennec, collagen matrix, NASH

    Abstract: LAENNEC: It is a multicomponent preparation based on Human placental hydrolysate, which has a proliferative effect on hepatocytes and fibrinolytic — on the connective tissue. This study proves fibrinolytic effect of drug “Laennec” in patients with nonalcoholic steatohepatitis during 4 months of monotherapy. This drug able to normalize marker of inflammation, cytolysis and cholestasis. Also it improves protein synthesis and the activity of antioxidant which leads to decrease in right hypochondrium pain, asthenic syndrome, manifestations of hepatic insufficiency and severity of fibrosis in liver.

      1. Gromova O.A. Torshchin I.Yu., Volkov A.Yu., Smarygin S.N., Nazarenko O.A., Karimova I.M. Preparat Laennek: elementnyi sostav i farmakologicheskoe deistvie. Plasticheskaya khirurgiya i kosmetologiya. 2011:2:327-333.
      2. Lazebnik L.B., Radchenko V.G., Golovanova E.V., Zvenigorodskaya L. A. Nealkogol'naya zhirovaya bolezn' pecheni: klinika, diagnostika, lechenie (rekomendatsii dlya terapevtov, 2-versiya). Eksperimental'naya i klinicheskaya gastroenterologiya – Experimental and Clinical Gastroenterology Journal. 2017;138(2):22-37.
      3. Maksimov V.A., Minushkin O.N., Pal'tsev A.I., Saifutdinov R.G., Chernyshev A.L., Gromova R.A., Gusakova E.V., Radchenko V.G., Lazebnik L.B. Rekomendatsii po primeneniyu gidrolizata chelovecheskoi platsenty pri zabolevaniyakh pecheni. Eksperimental'naya i klinicheskaya gastroenterologiya – Experimental and Clinical Gastroenterology Journal. 2016;136(12):75-77.
      4. Мinushkin O.N., Dibrova E.A., Karimova I.Ya., et al. «Laennek» – novyi gepatoprotektivnyi preparat dlya lecheniya steatogepatitov razlichnoi etiologii». Kremlevskaya meditsina. 2007;2:65-67.
      5. Minushkin O.N., Leont'ev S.I., Maslovskii L.V., et al. Primenenie diskriminantnoi schetnoi shkaly dlya otsenki fibroobrazovaniya v pecheni u bol'nykh s khronicheskimi gepatitami. Gepatologiya. 2005;1:16-24.
      6. Pavlov Ch.S., Zolotarevskii V.B., Tomkevich M.S. Vozmozhnosti obratimosti tsirroza pecheni. Rossiiskii zhurnal Gastroenterologii, Gepatologii, Koloproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2006;1:20-29.
      7. Pavlov Ch.S., Ivashkin V.T. Biopsiya pecheni: metodologiya i praktika segodnya. Rossiiskii zhurnal Gastroenterologii, Gepatologii, Koloproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2006;16(4):65-78.
      8. Pavlov Ch.S., Glushenkov D.V., Ivashkin V.T. Sovremennye vozmozhnosti elastometrii fibro- i akti-testa v diagnostike fibroza pecheni. Rossiiskii zhurnal Gastroenterologii, Gepatologii, Koloproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2008;4:43-52.
      9. Pavlov Ch.S., Zolotarevskii V.B., Tomkevich M.S. Vozmozhnosti obratimosti tsirroza pecheni. Rossiiskii zhurn al Gastroenterologii, Gepatologii, Koloproktologii – The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2006;1:20-29.
      10. Radchenko V.G., Seliverstov P.V., Ivanova V.F., Sitkin S.I. Algoritm lecheniya nealkogol'noi zhirovoi bolezni pecheni i rol' mitokhondrial'noi disfunktsii v ee razvitii. Фарматека. 2017;6:12-19.
      11. Radchenko V.G., Seliverstov P.V. Vozrastnye izmeneniya pecheni. Vestnik SZGMU im. I.I. Mechnikova. 2017;9(1):110-116.
      12. Seliverstov P.V., Radchenko V.G. Rol' mitokhondrial'noi tsitopatii pri steatoze u bol'nykh nealkogol'noi zhirovoi bolezn'yu pecheni. Effektivnaya farmakoterapiya. 2017;5:16-24.
      13. Severov M.V. Obratimost' fibroza i tsirroza pecheni pri HCV–infektsii. Gepatologicheskii forum. 2008;1:2-6.
      14. Storozhakov G.I., Ivkova A.N. Patogeneticheskie aspekty fibrogeneza pri khronicheskikh zabolevaniyakh pecheni. Klinicheskie perspektivy gastroenterologii, gepatologii. 2009;2:3-10.
      15. Sherlok Sh., Duli Dzh. Zabolevaniya pecheni i zhelchnykh putei. Prakticheskoe rukovodstvo. Мoscow, GEOTAR-MED, 2002. 864 p.
      16. Albanis E., Friedman S.L. Hepatic fibrosis. Pathogenesis and principles of therapy. Clin. Liver Dis. 2001;5:315-334.
      17. Arthur M.J. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. American Journal of Physiology, Gastrointestinal and Liver Physiology. 2000;279:G245-G249.
      18. Arthur M.J. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology. 2002;122:1525-1528.
      19. Asrani S.K., Talwalkar J.A., Kamath P.S., Shah V.H., Saracino G., Jennings L., et al. Role of magnetic resonance elastography in compensated and decompensated liver disease. J Hepatol. 2014;60:934-939.
      20. Bataller R., Brenner D.A. Liver fibrosis. The Journal of Clinical Investigation. 2005;115:209-218.
      21. Bataller R. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal / R. Bataller, K. E. North, D. A. Brenner // Hepatology. - 2003. - No. 37. - Р. 493-503.
      22. Bataller R. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal / R. Bataller, K. E. North, D. A. Brenner // Hepatology. - 2003. - No. 37. - Р. 493-503.
      23. Bataller R. et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells / R. Bataller et al. // Gastroenterology. - 2000. - No. 118. - Р. 1149-1156.
      24. Bataller R. et al. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver /R. Bataller et al. // Am. J. Physiol. Gastrointest. Liver Physiol. - 2003. - No. 285. - P. G642-G651.
      25. Bataller R. et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis / Bataller R. et al. // J. Clin. Invest. - 2003. - No. 112. - Р. 1383-1394.
      26. Benyon R. C. Is liver fibrosis reversible? / R. C. Benyon, J. P. Iredale // Gut. - 2000. - No. 46. - Р. 443-446.
      27. Brunt E. M. Nonalcoholic steatohepatitis / E. M. Brunt // Semin. Liver Dis. - 2004. - No. 24. - Р. 3-2.
      28. Brun P. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells / P. Brun, I. Castagliuolo, M. Pinzani, G. Palu, D. Martines // Am J Physiol Gastrointest Liver Physiol. - 2005. - Vol. 289, No. 3. - P. G571-G578.
      29. Cadranel J. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF) / J. Cadranel, P. Rufat, F. Degos // Hepatology. - 2000. - No 32. - P. 477-81.
      30. Canbay A. et al. Fas enhances fibrogenesis in the bile ductligated mouse: a link between apoptosis and fibrosis / A. Canbay et al. // Gastroenterology. - 2002. - No. 123. - Р. 1323-1330.
      31. Chen Y., et al. Hedgehog controls hepatic stellate cell fate by regulating metabolism / Y. Chen, S. S. Choi, G. A. Michelotti, I. S. Chan, M. Swiderska-Syn, G. F. Karaca, et al. // Gastroenterology. - 2012. -Vol. 143. - P. 1319-1329.
      32. De Alwis N. M. W. Non-alcoholic fatty liver: the mist gradually clear / N.M.W. De Alwis, C. P. Day // J Hepatol. - 2008. - No. 48. - P. S 105-S 112.
      33. Diego Garcia-Compean. Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management / Diego Garcia-Compean, Joel Omar Jaquez-Quintana, Jose Alberto Gonzalez-Gonzalez, Hector Maldonado-Garza// World J Gastroentrol. -2009. - Vol. 15. - No. 3. - P. 280-288.
      34. Gabele E. Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell / E. Gabele, D. A. Brenner, R. A. Rippe // Front. Biosci. - 2003. - No. 8. - D 69-D 77.
      35. Gilmore I. et al. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales / I. Gilmore, A. Burroughs, I. Murray-Lyon, et al. // An audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut. - 1995. -No. 36. - P. 437-41.
      36. Gressner A. M. Roles of TGF_beta in hepatic fibrosis / A. M. Gressner, R. Weiskirchen, K. Breitkopf, S. Dooley // Front. Biosci. - 2002. -No.7. - P. d793-d807.
      37. Ishak K. et al. Histological grading and staging of chronic hepatitis / K. Ishak, A. Baptista, L. Bianchi, et al. J. Hepatol. - 1995. - No. 2. - P. 696-99.
      38. Iredale J. P. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ / J. P. Iredale // J. Clin. Invest. - 2007. - Vol. 117, No. 3. - P. 539-548.
      39. Issa R. et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix crosslinking / R. Issa et al. // Gastroenterology. - 2004. - No. 126. - Р. 1795-1808.
      40. Kamada Y. et al. Enhanced carbon tetrachloride induced liver fibrosis in mice lacking adiponectin / Y. Kamada et al. // Gastroenterology. -2003. - No. 125. - Р. 1796-1807.
      41. Kanno K., Tazuma S., Chayama K. AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl (4) / K. Kanno, S. Tazuma, K. Chayama // Biochem. Biophys. Res. Commun. - 2003. - No. 308. - Р. 177-183.
      42. Kinnman N. Peribiliary myofibroblasts in biliarytype liver fibrosis / N. Kinnman, C. Housset // Front. Biosci. - 2002. - No. 7. - Р. 496-503.
      43. Knodell R., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis / R. Knodell, K. Ishak, W. Black, et al. // Hepatology. - 1981. - No. 4. -P.431-35.
      44. Lee Y. A., Wallace M. C., Friedman S. L. Pathobiology of liver fibrosis: a translational success story / Y. A. Lee, M. C. Wallace, S. L. Friedman // Gut. - 2015. - No. 64. - P. 830-41. doi: 10.1136/gutjnl-2014-306842.
      45. Macias-Barragan J. Update on the pathophysiology of liver fibrosis. / J. Macias-Barragan // Expert Rev Gastroenterol Hepatol. - 2010. - Vol. 4. - P. 459-472.
      46. Marra F. Chemokines in liver inflammation and fibrosis / F. Marra // Front. Biosci. - 2002. - No. 7. - P. 1899-1914.
      47. Mann D. A. Epigenetics in liver disease / D. A. Mann // Hepatology. - 2014. - Vol. 60. - P. 1418-1425.
      48. Magness S. T. A dual reporter gene transgenic mouse demonstrates heterognity in hepatic fibrogenic cell populations / S. T. Magness, R. Bataller, L. Yang, D. A. Brenner // Hepatology. - 2004. -No. 40. - Р. 1151-1159.
      49. Novo E. Redox mechanisms in hepatic chronic wound healing and fibrogenesis / E. Novo, M. Parola // Fibrogenesis Tissue Repair. - 2008. - P. 1-5.
      50. Novo E., et al. Vascular endothelial growth factor and angiopoietin-1 as hypoxia-dependent autocrine and paracrine factors stimulating migration and chemotaxis of activated human hepatic stellate cells / E. Novo, S. Cannito, E. Zamara, L. Valfre di Bonzo, A. Caligiuri, C. Cravanzola, et al. // Am J Pathol. - 2007. - Vol. 170. - P. 1942-1953.
      51. Oben J. A. et al. Hepatic fibrogenesis requires sympathetic neurotransmitters / J. A. Oben et al. // Gut. - 2004. - No. 53. - Р. 438-445.
      52. Ogawa E. et al. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with with pegylated interferon alpha-2d and ribavirin / E. Ogawa, N. Furusyo, K. Toyoda, et al. // Antiviral Res. - 2009. - Vol. 83, Issue-2. - P. 127-34.
      53. Olsen A. L., et al. Hepatic stellate cells require a stiff environment for myofibroblastic differentiation / A. L. Olsen, S. A. Bloomer, E. P. Chan, M. D. Gaca, P. C. Georges, B. Sackey, et al. // Am J Physiol Gastrointest Liver Physiol. - 2011. - Vol. 301. - P. G110-G118.
      54. Parsons C. J. Molecular mechanisms of hepatic fibrogenesis / C. J. Parsons, M. Takashima, R. A. Rippe // J Gastroenterol Hepatol. - 2007. - Vol. 22, No. 1. - P. 79-84.
      55. Pellicoro A. Liver fibrosis and repair: immune regulation of wound healing in a solid organ / A. Pellicoro, P. Ramachandran, J. P. Iredale, J. A. Fallowfield // Nat Rev Immunol. - 2014. - No.14- P. 181-194.
      56. Safadi R. et al. Immune stimulation of hepatic fibrogenesis by CD 8 cells and attenuation by transgenic interleukin_10 from hepatocytes / R. Safadi et al. // Gastroenterology. - 2004. - No. 127. - Р. 870-882.
      57. Sahai A. et al. Upregulation ofosteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model / A. Sahai, P. Malladi, H. Melin_Aldana // Am. J. Physiol.Gastrointest. Liver Physiol. - 2004. - No. 287. - Р. G264-G273.
      58. Sato M. Hepatic stellate cells: unique characteristics in cell biology and phenotype / M. Sato, S. Suzuki, H. Senoo // Cell Struct. Funct. - 2003. - No. 28. - Р. 105-112.
      59. Schwabe R. F. Human hepatic stellate cells express CCR 5 and RANTES to induce proliferation and migration / R. F. Schwabe, R. Bataller, D. A. Brenner // Am. J. Physiol. Gastrointest. Liver Physiol. - 2003. - No. 285. - P. G949-G958.
      60. Schnabl B. Interactions between the intestinal microbiome and liver diseases/ B. Schnabl, D. A. Brenner // Gastroenterology. -2014. - Vol. 146. - P. 1513-1524.
      61. Shek F. W. How can transforming growth factor beta be targeted usefully to combat liver fibrosis? / F. W. Shek, R. C. Benyon // Eur. J. Gastroenterol. Hepatol. - 2004. - No. 16. - Р. 123-126.
      62. Streetz K. L. et al. Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases / K. L. Streetz et al. // Hepatology. - 2003. - No. 38. - Р. 218-229.
      63. Takehara T. et al. Hepatocyte_specific disruption of BclxLleads to continuous hepatocyte apoptosis and liver fibrotic responses / T. Takehara et al. // Gastroenterology. - 2004. - No. 127. - Р. 1189-1197.
      64. Ueberham E. et al. Conditional tetracycline regulated expression of TGF_beta1 in liver of transgenic mice leads to reversible intermediary fibrosis / E. Ueberham et al. // Hepatology. - 2003. - No. 37. - Р. 1067-1078.
      65. Wang H. Effect of acid-sensing ion channel 1a on the process of liver fibrosis under hyperglycemia / H. Wang, Y. H. Wang, F. Yang, X. F. Li // Biochemical and Biophysical Research Communications. - 2015. - Vol. 468. - No. 4. - P. 758-765. www.doi.org/10.1016/j.bbrc.2015.11.029
      66. Yoshida T. et al. SOCS 1 is a suppressor of liver fibrosis and hepatitis_induced carcinogenesis / T. Yoshida et al. // J. Exp. Med. - 2004. - No. 199. - Р.1701-1707.
      67. Yoshiji H. et al. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenicmouse / H. Yoshiji et al. // Hepatology. - 2002. - No. 36. - Р. 850-860.
      68. Yu C. et al. Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride_induced hepatic injury and fibrogenesis / C. Yu et al. // Am. J. Pathol. - 2003. - No. 163. - Р. 1653-1662.

    Full text is published :
    Lazebnik L.B., Radchenko V.G., Seliverstov P.V., Sitkin S.I. et al. THE CONTEMPORARY UNDERSTANDING OF LIVER FIBROSIS AND APPROACHES TO TREATMENT IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS. Experimental and Clinical Gastroenterology Journal. 2017;148(12):98-108
    Read & Download full text

    1. V. I. Vernadsky Crimean Federal University

    Abstract: Article provides Russian translation of first description of major duodenal papilla (Vater’s papilla) found in work of English physician and anatomist Samuel Collins (1618-1710). Brief biographical sketch is given and his contribution to comparative anatomy is described.

      1. Волошин Н. А., Светлицкий А. А., Зинич Е. Л. Основные закономерности происхождения анатомической терминологии // Вісник проблем біології і медицини. - 2016. - № 2(1). - С. 143-146.
      2. Сперанский В. С., Гончаров Н. И. Очерки истории анатомии. - Волгоград: Издатель, 2012. - 216 с.
      3. Stigler S. M. Stigler’s law of eponymy // Transactions of the New York Academy of Sciences. - 1980. - Vol. 39, Is.1. - P. 147-157.
      4. Кутя С. А. Алессандро Акиллини и Алессандро Бенедетти - два позабытых анатома (к 500-летию со дня их смерти) // Клін. анат. та опер. хір. - 2012. - № 4. - С. 135-137.
      5. Kutia S. A. Eponyms in biliary tree // Экспериментальная и клиническая гастроэнтерология. - 2014. - № 10(110). - С. 106-110.
      6. Kutia S. A., Lyashchenko O. I., Smirnova S. N., Polishchuk E. A. Venous eponyms in digestive system // Экспериментальная и клиническая гастроэнтерология. - 2016. - № 4. - С. 101-104.
      7. Кутя С. А., Сатаева Т. П., Николаева Н. Г., Принцева Н. Ю., Мороз Г. А. История открытия бульбоуретральных желез // Урология. - 2016. - № 3. - С. 108-111.
      8. Collins S. A systeme of anatomy, treating of the body of man, beasts, birds, fish, insects, and plants. - London: Thomas Newcomb, 1685. - 678p.
      9. Kutia S. A., Sataieva T. P., Kriventsov M. A., Polishchuk E. A. Pancreas: history in a timeline // Экспериментальная и клиническая гастроэнтерология. - 2017. - № 5. - С. 74-78.
      10. Кутя С. А., Смирнова С. Н., Лященко О. И. Знаменательные даты в истории анатомии в 2015 году // Журнал анатомии и гистопатологии. - 2015. - Т. 4, № 4. - С. 80-82.
      11. Munk W. The roll of the Royal College of physicians of London. Vol. I. - 1861. - London: Longman, Green, Longman, and Roberts, Paternoster row. - 472p.
      12. Kruger L. An early illustrated comparative anatomy of the brain: Samuel Collins’ “A systeme of anatomy” (1685) and the emergence of comparative neurology in 17th century England // J. Hist. Neurosci. - 2004. - Vol. 13, № 3. - Р. 197-219.


    Full text is published :
    Kutia S.A.,Lyashchenko O.I.,Smirnova S.N.,Polishchuk E.A. SAMUEL COLLINS (1618-1710) AND FIRST DESCRIPTION OF PAPILLA DUODENI MAJOR. Experimental and Clinical Gastroenterology Journal. 2017;148(12):110-112
    Read & Download full text